日本臨牀　別冊　腎臓症候群（第3版）IV

出版社： 日本臨牀社
発行日： 2022-11-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 腎臓症候群（第3版）IV
電子書籍版： 2022-11-30 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　腎臓症候群（第3版）IV
    　　　―その他の腎臓疾患を含めて―

    X．保存期腎不全
    　１．慢性腎臓病に伴う骨・ミネラル代謝異常（CKD-MBD）骨粗鬆症も含めて
    　２．レストレスレッグ症候群
    　３．腎性貧血
    　４．CRA(cardio-renal-anemia)症候群
    　５．慢性腎臓病による成長障害
    　６．二次性副甲状腺機能亢進症（保存期）
    　７．尿毒症症候群
    　８．尿毒症性ニューロパチー
    　９．尿毒症性ミオパチー
    　10．尿毒症性脂質異常症
    　11．尿毒症性関節炎
    　12．尿毒症性心筋症
    　13．尿毒症性心外膜炎
    　14．尿毒症性脳症
    　15．尿毒症性肺，尿毒症性胸膜炎

    XI. 急性腎障害の病態
    　１．運動誘発性急性腎不全
    　２．急性腎炎，ネフローゼ症候群にみられる急性腎不全
    　３．妊娠中ならびに産褥期の急性腎不全
    　４．術後急性腎障害
    　５．多臓器不全と急性腎不全
    　６．腎乳頭壊死
    　７．腎皮質壊死
    　８．腎後性腎不全

    XII．維持透析患者にみられる病態
    　１．CAPD横隔膜交通症
    　２．腹膜透析関連腹膜炎 (CAPD腹膜炎)
    　３．CAPDカテーテル関連合併症
    　４．腹膜透析と被嚢性腹膜硬化症
    　５．カルシフィラキシス
    　６．サイコネフロロジー
    　７．へパリン起因性血小板減少症
    　８．鉄代謝異常
    　９．血管石灰化
    　10．透析患者の栄養障害
    　11．消化管疾患：消化管出血
    　12．虚血性心疾患
    　13．視力障害
    　14．長期血液透析患者に生じる手根管症候群について
    　15．腎細胞癌
    　16．透析アミロイドーシス
    　17．透析感染症
    　18．透析関節症、透析肩症、透析脊椎症
    　19．透析心，心不全
    　20．透析脳症
    　21．バスキュラーアクセス合併症
    　22．脳血管障害
    　23．透析皮膚そう痒症
    　24．不均衡症候群
    　25．不整脈
    　26．無形成骨
    　27. 二次性副甲状腺機能亢進症（透析期）
    　28．フレイル・サルコペニア

    XIII．中毒性腎障害(薬物性腎障害，化学物質による腎障害)
    　１．覚醒剤による腎障害：法医学の立場から
    　２．漢方薬による腎障害
    　３．降圧薬による腎障害
    　４．抗ウイルス薬と腎障害
    　５．抗微生物薬による腎障害
    　６．向精神薬・抗痙攣薬による腎障害：悪性症候群による急性腎障害
    　７．抗腫瘍薬による腎障害
    　８．抗リウマチ薬による腎障害
    　９．食中毒による腎障害
    　10．造影剤による急性腎障害
    　11．マムシ咬症における急性腎機能障害
    　12．非ステロイド系薬剤による腎障害
    　13．非薬物性化学物質(農薬，金属化合物，有機溶媒など)による腎障害
    　14． 免疫抑制薬による腎障害（カルシニューリン阻害薬による腎障害）
    　15．有毒キノコによる中毒性腎障害
    　16．利尿薬による腎障害
    　17．VEGF阻害薬による腎障害
    　18. 免疫チェックポイント阻害薬による腎障害
    　19. マルチキナーゼ阻害薬による腎障害

    XIV．その他
    　１．Ormond症候群(後腹膜線維症)
    　２．TUR症候群
    　３．腎結石・腎石灰化症
    　４．腎疾患による二次性赤血球増加症
    　５．腎性全身性線維症
    　６．体位性タンパク尿（起立性タンパク尿）
    　７．特発性腎出血
    　８．熱性腎症
    　９．閉塞性腎症
    　10．放射線腎症
    　11．遊走腎(腎下垂)

    XV.　補遺
    　１．先天性・遺伝性疾患の補遺
    　　（１）ファブリー病

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

X 保存期腎不全

P.9 掲載の参考文献
1) 花房規男, ほか : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
2) Payne RB, et al : Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4 : 643-646, 1973.
PubMed
3) Isakova T, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011.
PubMed
4) Nakano C, et al : Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7 : 810-819, 2012.
PubMed
5) Bellasi A, et al : Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 6 : 883-891, 2011.
PubMed
6) Voormolen N, et al : High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22 : 2909-2916, 2007.
PubMed
7) Faul C, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011.
PubMed
8) Scialla JJ, et al : Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25 : 349-360, 2014.
PubMed
9) エビデンスに基づくCKD診療ガイドライン 2018 (日本腎臓学会編), 第7章 CKD-MBD, p41, 東京医学社, 2018.
 
10) de Zeeuw D, et al : Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) : a randomised controlled trial. Lancet 376 : 1543-1551, 2010.
PubMed
11) Kazama JJ, et al : Uremic osteoporosis. Kidney Int Suppl (2011) 3 : 446-450, 2013.
PubMed
12) Naylor KL, et al : Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function. Clin J Am Soc Nephrol 11 : 2032-2040, 2016.
PubMed
13) Iguchi A, et al : Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency. Nephron 131 : 161-166, 2015.
PubMed
14) Shima H, et al : Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients. BMC Res Notes 11 : 363, 2018.
PubMed
15) Honda H, et al : Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels. Blood Purif 47 (suppl 2) : 63-69, 2019.
 
16) Flamme I, et al : FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One 12 : e0186979, 2017.
PubMed
17) Coe LM, et al : FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289 : 9795-9810, 2014.
PubMed
18) Zisman AL, et al : Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 19 : 335-342, 2010.
 
19) Nakai K, et al : Parathyroid enlargement at dialysis initiation in patients with chronic kidney diseases. Ther Apher Dial 17 : 24-29, 2013.
PubMed
P.13 掲載の参考文献
1) 伴野麻悠子, ほか : 血液透析患者におけるレストレスレッグス症候群と生命予後の関連. 日本透析医学会雑誌 48 : 45-50, 2015.
 
2) 井上雄一, ほか (編) : Restless Legs Syndrome, アルタ出版, 2008.
 
3) Berger K, et al : Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 164 : 196-202, 2004.
PubMed
4) Pantaleo NP, et al : Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep Med 11 : 310-313, 2010.
PubMed
5) Yeh P, et al : Restless legs syndrome : a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath 16 : 987-1007, 2012.
PubMed
6) Ondo W, Jankovic J : Restless legs syndrome : clinicoetiologic correlates. Neurology 47 : 1435-1441, 1996.
PubMed
7) Phillips B, et al : Epidemiology of restless legs symptoms in adults. Arch Intern Med 160 : 2137-2141, 2000.
PubMed
8) Mizuno S, et al : CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 14 : 43-47, 2005.
PubMed
9) Nelson C, et al : In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 127 : 2282-2288, 1997.
PubMed
10) Ben-Shachar D, et al : Effect of iron chelators on dopamine D2 receptors. J Neurochem 45 : 999-1005, 1985.
PubMed
11) Sun ER, et al : Iron and the restless legs syndrome. Sleep 21 : 371-377, 1998.
PubMed
12) Giannaki CD, et al : Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients : an evidence-based review. Kidney Int 85 : 1275-1282, 2014.
PubMed
13) Winkelmann J, et al : Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 17 : 1072-1076, 2002.
PubMed
14) Alarcon JC, et al : Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes : COREXH Registry. Blood Purif 50 : 110-118, 2021.
PubMed
15) Roger SD, et al : Possible relation between restless legs and anemia in renal dialysis patients. Lancet 337 : 1551, 1991.
PubMed
16) Kawauchi A, et al : Restless legs syndrome in hemodialysis patients : health-related quality of life and laboratory data analysis. Clin Nephrol 66 : 440-446, 2006.
PubMed
17) Wetter TC, et al : Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. Mov Disord 13 : 820-824, 1998.
PubMed
18) Allen RP, et al : Restless legs syndrome : diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 : 101-119, 2003.
PubMed
19) Trenkwalder C, et al : The restless legs syndrome. Lancet Neurol 4 : 465-475, 2005.
PubMed
20) Oertel WH, et al : State of the art in restless legs syndrome therapy : practice recommendations for treating restless legs syndrome. Mov Disord 22 (Suppl 18) : S466-475, 2007.
 
21) Silber MH, et al : An algorithm for the management of restless legs syndrome. Mayo Clin Proc 79 : 916-922, 2004.
PubMed
22) Kavanagh D, et al : Restless legs syndrome in patients on dialysis. Am J Kidney Dis 43 : 763-771, 2004.
PubMed
23) Kambampati S, et al : Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis : A Literature Review. Cureus 12 : e9965, 2020.
PubMed
24) 脇川健, ほか : 血液透析患者のレストレスレッグス症候群に対するプラミペキソールの臨床効果についての検討. 日本透析医学会雑誌 44 : 1155-1161, 2011.
 
25) Giannaki CD, et al : Periodic limb movements in sleep contribute to further cardiac structure abnormalities in hemodialysis patients with restless legs syndrome. J Clin Sleep Med 9 : 147-153, 2013.
PubMed
26) Li Y, et al : Prospective study of restless legs syndrome and coronary heart disease among women. Circulation 126 : 1689-1694, 2012.
PubMed
27) Molnar MZ, et al : Association of incident restless legs syndrome with outcomes in a large cohort of US veterans. J Sleep Res 25 : 47-56, 2016.
 
28) Winkelman JW, et al : Associations of Incident Cardiovascular Events With Restless Legs Syndrome and Periodic Leg Movements of Sleep in Older Men, for the Outcomes of Sleep Disorders in Older Men Study (MrOS Sleep Study). Sleep 40 : zsx023, 2017.
PubMed
29) Li Y, et al : Prospective study of restless legs syndrome and total and cardiovascular mortality among women. Neurology 90 : e135-e141, 2018.
PubMed
P.18 掲載の参考文献
1) Sofue T, et al : Prevalence of anemia in patients with chronic kidney disease in Japan : A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15 : e0236132, 2020.
PubMed
2) Yamazaki S, et al : A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun 4 : 1950, 2013.
PubMed
3) Babitt JL, Lin HY : Mechanisms of anemia in CKD. J Am Soc Nephrol 23 : 1631-1634, 2012.
PubMed
4) Drueke TB, et al : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006.
PubMed
5) Singh AK, et al : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006.
PubMed
6) Pfeffer MA, et al : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 : 2019-2032, 2009.
PubMed
7) Gandra SR, et al : Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia : a systematic review. Am J Kidney Dis 55 : 519-534, 2010.
PubMed
8) Sugahara M, et al : Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int 92 : 306-312, 2017.
PubMed
9) Nangaku M, et al : Safety of daprodustat in patients with anemia of chronic kidney disease : a pooled analysis of phase 3 studies in Japan. Ther Apher Dial, 2022. (DOI : 10.1111/1744-9987.13839)
 
10) Sepah YJ, et al : Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. Kidney Int Rep 7 : 763-775, 2022.
PubMed
11) Provenzano R, et al : Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD : Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol 16 : 1190-1200, 2021.
PubMed
12) Singh AK, et al : Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med 385 : 2313-2324, 2021.
PubMed
13) Chertow GM, et al : Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med 384 : 1589-1600, 2021.
PubMed
P.22 掲載の参考文献
1) Klip IT, et al : The additive burden of iron deficiency in the cardiorenal-anaemia axis : scope of a problem and its consequences. Eur J Heart Fail 16 : 655-662, 2014.
PubMed
2) Alnuwaysir RIS, et al : Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome : findings from the BIOSTAT-CHF study. Eur J Heart Fail 24 : 192-204, 2022.
PubMed
3) McDonagh TA, et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021.
PubMed
4) Mohanram A, et al : Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66 : 1131-1138, 2004.
PubMed
5) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
6) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 : 253-259, 2000.
PubMed
7) Agarwal R, et al : Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease : the FIDELITY pooled analysis. Eur Heart J 43 : 474-484, 2022.
PubMed
8) Heerspink HJL, et al : Dapagliflozin in Patients with Chronic Kidney Disease. Reply. N Engl J Med 384 : 389-390, 2021.
PubMed
9) Zannad F, et al : SGLT2 inhibitors in patients with heart failure with reduced ejection fraction : a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396 : 819-829, 2020.
PubMed
10) Swedberg K, et al : Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 : 1210-1219, 2013.
PubMed
11) Heidenreich PA, et al : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79 : e263-e421, 2022.
 
12) Tsutsui H, et al : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83 : 2084-2184, 2019.
PubMed
13) Chopra VK, et al : Anaemia, iron deficiency and heart failure in 2020 : facts and numbers. ESC Heart Fail 7 : 2007-2011, 2020.
PubMed
14) Ponikowski P, et al : Ferric carboxymaltose for iron deficiency at discharge after acute heart failure : a multicentre, double-blind, randomised, controlled trial. Lancet 396 : 1895-1904, 2020.
PubMed
15) Singh AK, et al : Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med 385 : 2313-2324, 2021.
PubMed
P.27 掲載の参考文献
1) Kang NR, et al : Mental health and psychosocial adjustment in pediatric chronic kidney disease derived from the KNOW-Ped CKD study. Pediatr Nephrol 34 : 1753-1764, 2019.
PubMed
2) Furth SL, et al : Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol 17 : 450-455, 2002.
PubMed
3) Broyer M, et al : Long-term social outcome of children after kidney transplantation. Transplantation 77 : 1033-1037, 2004.
PubMed
4) Drube J, et al : Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 15 : 577-589, 2019.
PubMed
5) Rees L : Growth hormone therapy in children with CKD after more than two decades of practice. Pediatr Nephrol 31 : 1421-1435, 2016.
PubMed
6) Roelfsema V, Clark RG : The growth hormone and insulin-like growth factor axis : its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12 : 1297-1306, 2001.
PubMed
7) 服部元史 : 成長障害. 腎と透析 61 (増刊号) : 98-102, 2006.
 
8) Shaw V, et al : Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 35 : 519-531, 2020.
PubMed
9) Kraut JA, Madias NE : Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 26 : 19-28, 2011.
 
10) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日本透析医学会雑誌 45 : 301-356, 2012.
 
11) 2015年版日本透析医学会 : 慢性腎臓病患者における腎性貧血治療のガイドライン. 日本透析医学会雑誌 49 : 89-158, 2016.
 
12) 日本透析医学会 : 維持血液透析ガイドライン : 血液透析処方. 日本透析医学会雑誌 46 : 587-632, 2013.
 
13) Bonthuis M, et al : Growth in children on kidney replacement therapy : a review of data from patient registries. Pediatr Nephrol 36 : 2563-2574, 2021.
PubMed
14) Fine RN : Management of growth retardation in pediatric recipients of renal allografts. Nat Clin Pract Nephrol 3 : 318-324, 2007.
PubMed
15) 腎移植後内科・小児科系合併症の診療ガイドライン 2011 (日本臨床腎移植学会ガイドライン作成委員会編), 日本医学館, 2011.
 
P.30 掲載の参考文献
1) Fukagawa M, et al : Clinical practice guideline for the management of chronic kidney diseasemineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013.
PubMed
2) Bricker NS : On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 286 : 1093-1099, 1972.
PubMed
3) Hasegawa H, et al : Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78 : 975-980, 2010.
PubMed
4) Schumock GT, et al : Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin 24 : 3037-3048, 2008.
PubMed
5) Toapanta Gaibor NG, et al : PTH levels and not serum phosphorus levels are a predictor of the progression of kidney disease in elderly patients with advanced chronic kidney disease. Nefrologia 37 : 149-157, 2017.
 
6) Scialla JJ, et al : Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 24 : 125-135, 2013.
PubMed
7) Bozic M, et al : Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events : an analysis from the NEFRONA cohort. Nephrol Dial Transplant 37 : 663-672, 2022.
PubMed
8) Xu Y, et al : Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J 14 : 2213-2220, 2021.
PubMed
9) Ketteler M, Ambuhl P : Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. J Nephrol 34 : 1405-1418, 2021.
PubMed
P.36 掲載の参考文献
1) Rosner MH, et al : Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol 16 : 1918-1928, 2021.
PubMed
2) Watanabe Y, et al : Japanese society for dialysis therapy clinical guideline for "hemodialysis initiation for maintenance hemodialysis". Ther Apher Dial 19 (Suppl 1) : 93-107, 2015.
 
3) Cooper BA, et al : A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363 : 609-619, 2010.
PubMed
4) Doi T, et al : Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care. PLoS One 10 : e0129180, 2015.
PubMed
5) Go AS, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296-1305, 2004.
PubMed
6) Fellstrom BC, et al : Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 : 1395-1407, 2009.
PubMed
7) Wanner C, et al : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005.
PubMed
8) Baigent C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 : 2181-2192, 2011.
PubMed
9) Matsuo K, et al : Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate. Toxins (Basel) 7 : 3155-3166, 2015.
PubMed
10) Nakano T, et al : Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling. Circulation 139 : 78-96, 2019.
PubMed
11) Isaka Y, et al : Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. J Am Soc Nephrol 32 : 723-735, 2021.
PubMed
12) Shoji T, et al : Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism : A Randomized Clinical Trial. Clin J Am Soc Nephrol 16 : 599-612, 2021.
PubMed
13) Hayashi T, et al : Initial responsiveness to darbepoetin alfa and its contributing factors in nondialysis chronic kidney disease patients in Japan. Clin Exp Nephrol 25 : 110-119, 2021.
PubMed
14) Nii-Kono T, et al : Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71 : 738-743, 2007.
PubMed
P.40 掲載の参考文献
1) Marin OS, Tyler HR : Hereditary interstitial nephritis associated with polyneuropathy. Nephrology 11 : 999-1005, 1961.
 
2) Asbury AK, et al : Uremic polyneuropathy. Arch Neurol 8 : 413-428, 1963.
PubMed
3) Bolton CF : Peripheral neuropathies associated with chronic renal failure. Can J Neurol Sci 7 : 89-96, 1980.
PubMed
4) Babb AL, et al : The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17 : 81-91, 1971.
PubMed
5) Funck-Brentano JL, et al : Characterization of a 1100-1300 MW uremic neurotoxin. Trans Am Soc Artif Intern Organs 22 : 163-167, 1976.
PubMed
6) Clements RS, et al : Raised plasma-myoinositol levels in uraemia and experimental neuropathy. Lancet 1 : 1137-1141, 1973.
PubMed
7) Reznek RH, et al : Plasma-myoinositol concentrations in uraemic neuropathy. Lancet 1 : 675-676, 1977.
PubMed
8) Avram MM, et al : Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 298 : 1000-1003, 1978.
PubMed
9) Goldstein DA, et al : Effect of parathyroid hormone and uremia on peripheral nerve calcium and motor nerve conduction velocity. J Clin Invest 62 : 88-93, 1978.
PubMed
10) Thomas PK : Screening for peripheral neuropathy in patients treated by chronic hemodialysis. Muscle Nerve 1 : 396-399, 1978.
PubMed
11) Dyck PJ, et al (ed) : Peripheral Neuropathy. Vol 1, p686-705, WB Saunders, Philadelphia, 1993.
 
P.43 掲載の参考文献
1) Campistol JM : Uremic myopathy. Kidney Int 62 : 1901-1913, 2002.
PubMed
2) Cruz-Jentoft AJ, et al : Sarcopenia : European consensus on definition and diagnosis : Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 : 412-423, 2010.
 
3) Fahal IH : Uraemic sarcopenia : aetiology and implications. Nephrol Dial Transplant 29 : 1655-1665, 2014.
PubMed
4) Kim JK, et al : Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr 33 : 64-68, 2014.
PubMed
5) Isoyama N, et al : Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 9 : 1720-1728, 2014.
PubMed
6) Gamboa JL, et al : Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep 4 : e12780, 2016.
PubMed
7) Yazdi PG, et al : Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med 6 : 532-539, 2013.
PubMed
8) Roshanravan B, et al : CKD and Muscle Mitochondrial Energetics. Am J Kidney Dis 68 : 658-659, 2016.
PubMed
9) Miro O, et al : Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure. Am J Kidney Dis 39 : 1025-1031, 2002.
PubMed
10) Sala E, et al : Impaired muscle oxygen transfer in patients with chronic renal failure. Am J Physiol Regul Integr Comp Physiol 280 : R1240-R1248, 2001.
PubMed
11) Tamaki M, et al : Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase. Kidney Int 85 : 1330-1339, 2014.
PubMed
12) Wagner PD, et al : Muscle angiogenic growth factor gene responses to exercise in chronic renal failure. Am J Physiol Regul Integr Comp Physiol 281 : R539-R546, 2001.
PubMed
13) John SG, et al : Natural History of Skeletal Muscle Mass Changes in Chronic Kidney Disease Stage 4 and 5 Patients : An Observational Study. PLoS One 8 : e65372, 2013.
PubMed
14) Hewitt NA, et al : Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8 : 1143-1149, 2013.
PubMed
15) Shoji T, et al : Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism : A Randomized Clinical Trial. Clin J Am Soc Nephrol 16 : 599-612, 2021.
PubMed
16) Vaux EC, et al : Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 97 : c41-c48, 2004.
PubMed
17) Qian FY, et al : Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease. Am J Physiol Renal Physiol 317 : F1265-F1273, 2019.
 
18) Heiwe S, Jacobson SH : Exercise training in adults with CKD : a systematic review and meta-analysis. Am J Kidney Dis 64 : 383-393, 2014.
PubMed
19) Dienemann T, et al : Changes in Body Composition, Muscle Strength, and Fat Distribution Following Kidney Transplantation. Am J Kidney Dis 78 : 816-825, 2021.
PubMed
P.48 掲載の参考文献
1) Bagdade JD, et al : Hypertriglyceridemia : A metabolic consequence of chronic renal failure. N Engl J Med 279 : 181-185, 1968.
PubMed
2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
3) Massry SG, et al : Disorders of Lipid Metabolism in Uremia, In : Diseases of the Kidney (ed by Schrier RW, Gottschalk CW), p2666-2670, Little Brown, Boston, 1997.
 
4) Kwan BC, et al : Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18 : 1246-1261, 2007.
PubMed
5) Ferro CJ, et al : Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 14 : 727-749, 2018.
PubMed
6) Attman PO, et al : Dyslipoproteinemia in diabetic renal failure. Kidney Int 42 : 1381-1389, 1992.
PubMed
7) Attman PO, Alaupovic P : Lipid abnormalities in chronic renal insufficiency. Kidney Int Suppl 31 : S16-S23, 1991.
PubMed
8) Rubies-Prat J, et al : High-density lipoprotein cholesterol subfractions in chronic uremia. Am J Kidney Dis 9 : 60-65, 1987.
PubMed
9) Bagdade J, et al : Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 87 : 38-48, 1976.
 
10) Nestel PJ, et al : Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 307 : 329-333, 1982.
PubMed
11) Kimura H, et al : Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients : associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size. Nephrology (Carlton) 16 : 558-566, 2011.
PubMed
12) Speer T, et al : Lipoproteins in chronic kidney disease : from bench to bedside. Eur Heart J 42 : 2170-2185, 2021.
PubMed
13) Attman PO, et al : Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32 : 368-375, 1987.
PubMed
14) Grutzmacher P, et al : Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 50 : 103-111, 1988.
PubMed
15) Attman PO, Alaupovic P : Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57 : 401-410, 1991.
PubMed
16) Bergesio F, et al : Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 38 : 264-270, 1992.
PubMed
17) McCosh EJ, et al : Hypertriglyceridemia in patients with chronic renal insufficiency. Am J Clin Nutr 28 : 1036-1043, 1975.
PubMed
18) Chan MK, et al : Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis : the relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 17 : 183-190, 1982.
PubMed
19) Schaefer F, et al : Disorders of Lipid Metabolism in Uremial failure. In : Oxford Textbook of Clinical Nephrology (ed by Cameron S, et al), p1254-1258, Oxford University Press, Oxford, 1992.
 
20) Avram MM, et al : Cholesterol and lipid disturbances in renal disease : the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 87 : 55N-60N, 1989.
PubMed
21) Prichard SS : Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 14 (9 Suppl 4) : S315-320, 2003.
 
22) Law S, Davenport A : The effect of glucose absorption from peritoneal dialysates on changes in lipid profiles in prevalent peritoneal dialysis patients. Perit Dial Int 41 : 115-117, 2021.
PubMed
23) Baigent C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 : 2181-2192, 2011.
PubMed
24) Fellstrom BC, et al : Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 : 1395-1407, 2009.
PubMed
25) Holdaas H, et al : Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 22 : 1335-1341, 2011.
PubMed
P.55 掲載の参考文献
1) Gejyo F, et al : A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Boichem Biophys Res Commun 129 : 701-706, 1985.
 
2) Ogawa H, et al : Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 28 : 199-204, 1987.
PubMed
3) 奥津一郎 : 長期血液透析患者における手根管症候群および肩インピンジメント症候群の鏡視手術-新しい疾患概念SLACS-. 日本透析医学会雑誌 29 : 1363-1369, 1996.
 
4) 小川洋史, ほか : 尿毒症性関節炎における滑膜, 靱帯の病理組織学的検討-特にMacrophage系細胞の検討-. 腎と透析 32 (別冊) : 180-184, 1992.
 
5) 内木宏延 : 透析アミロイドーシス発症の分子機構. 医学のあゆみ 229 : 377-382, 2009.
Medical*Online
6) Linke RP, et al : Lysine-specific cleavage of beta 2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36 : 675-681, 1989.
PubMed
7) Ogawa H, et al : Detection of novel beta 2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 30 : 158-163, 1988.
PubMed
8) Miyata T, et al : beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92 : 1243-1252, 1993.
 
9) Yamada T, et al : A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits. Ann Clin Lab Sci 24 : 243-249, 1994.
 
10) Pagani C, et al : Carpal tunnel syndrome in long-term dialysis patients. Contrib Nephrol 45 : 82-96, 1985.
PubMed
11) 石黒直樹, ほか : 透析患者の手根管症候群について. 現代医療 38 : 13-18, 1990.
 
12) 小川洋史, ほか : 骨嚢胞性病変形成のメカニズムについて, 臨床透析 10 : 77-89, 1994.
 
13) 小川洋史, ほか : 透析アミロイドーシスの臨床. [改定第3版] 透析患者の骨病変-その見方と考え方 (黒川清, ほか編), p397-407, 日本メディカルセンター, 1993.
 
14) 伊与田一人, ほか : 透析患者に合併する肩関節病変について, 第34回日本腎臓学会総会予稿集, 404, 1991.
 
15) Kuntz D, et al : Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27 : 369-375, 1984.
PubMed
16) 丸山弘樹, ほか : 長期血液透析患者における破壊性脊椎関節症destructive spondylarthropathyの臨床的検討. 日本透析療法学会雑誌 22 : 741-748, 1989.
 
17) Rousselin B, et al : Pseudotumor of the craniocervical junction during long-term hemodialysis. Arthritis Rheum 33 : 1567-1573, 1990.
PubMed
18) 小川洋史, ほか : 透析アミロイドーシスの一症候としてのBaker's cystについて. 腎と透析 25 (別冊) : 194-197, 1988.
 
19) 佐藤恵, ほか : 被膜にアミロイド沈着を認めたtumoral calcinosisの一剖検例. 日本透析療法学会雑誌 24 : 1004, 1991.
 
20) 吾妻真幸, ほか : 腫瘤状硬膜外アミロイド沈着により腰髄圧迫, 下肢麻痺を来した透析患者の一例. 日本透析療法学会雑誌 24 : 1004, 1991.
 
21) 青柳竜治 : 超音波画像診断による透析患者の肩および股関節包膨隆度の検討. 日本透析療法学会雑誌 25 : 1343-1350, 1992.
 
22) 下条文武 : 透析合併症の対策-透析アミロイドーシス. 日本内科学会雑誌 84 : 1673-1677, 1995.
 
23) 内藤正俊 : 透析患者の破壊性脊椎関節症 (DSA) 症例について. 関節外科 9 : 907-913, 1990.
 
24) 大西哲朗, 佐藤公治 : 長期透析患者における脊椎手術療法の検討. 日本透析医学会雑誌 39 : 275-280, 2006.
 
25) Hatano M, et al : Dialysis-related carpal tunnel syndrome in the past 40 years. Clin Exp Nephrol 26 : 68-74, 2022.
PubMed
26) Hoshino J, et al : Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant 31 : 595-602, 2016.
PubMed
27) Yamamoto S, et al : Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15 : 126-133, 2004.
 
28) Naiki H, et al : Molecular pathogenesis of human amyloidosis : Lessons from β2-microglobulinrelated amyloidosis. Pathol Int 66 : 193-201, 2016.
 
P.60 掲載の参考文献
1) Nitta K, et al : Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease : findings from the CKD-JAC study. Clin Exp Nephrol 23 : 85-98, 2019.
 
2) Paoletti E, et al : Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 46 : 320-327, 2005.
 
3) Nardi E, et al : Left ventricular hypertrophy in chronic kidney disease : A diagnostic criteria comparison. Nutr Metab Cardiovasc Dis 31 : 137-144, 2021.
PubMed
4) 図説「わが国の慢性透析療法の現況」. 日本透析医学会, 2021. [https://docs.jsdt.or.jp/overview/index.html]
 
5) Sadoshima J, et al : Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 : 977-984, 1993.
PubMed
6) Franssen CF, Navis G : Chronic kidney disease : RAAS blockade and diastolic heart failure in chronic kidney disease. Nat Rev Nephrol 9 : 190-192, 2013.
PubMed
7) Fiorillo C, et al : Cardiac volume overload rapidly induces oxidative stress-mediated myocyte apoptosis and hypertrophy. Biochim Biophys Acta 1741 : 173-182, 2005.
PubMed
8) Kuma A, et al : Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease. FASEB J 34 : 8296-8309, 2020.
PubMed
9) Schluter KD, Piper HM : Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37 : 34-41, 1998.
PubMed
10) Touchberry CD, et al : FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 304 : E863-873, 2013.
PubMed
11) Hu MC, et al : Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26 : 1290-1302, 2015.
PubMed
12) Sibal L, et al : The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev 6 : 82-90, 2010.
PubMed
13) London GM : Cardiovascular disease in chronic renal failure : pathophysiologic aspects. Semin Dial 16 : 85-94, 2003.
PubMed
14) Heerspink HJL, et al : Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383 : 1436-1446, 2020.
PubMed
15) Mori T, et al : Treatment of renal congestion by tolvaptan. Hypertens Res 42 : 745-748, 2019.
PubMed
P.66 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Renfrew R, et al : Pericarditis and renal failure. Annu Rev Med 31 : 345-360, 1980.
PubMed
3) Bright R : Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep 1 : 338-379, 1836.
 
4) Bailey GL, et al : Uremic pericarditis. Clinical features and management. Circulation 38 : 582-591, 1968.
PubMed
5) 田部井薫 : 尿毒症性心外膜炎 (心嚢炎). 臨牀透析 26 : 585-592, 2010.
 
6) Bentata Y, et al : Uremic pericarditis in patients with End Stage Renal Disease : Prevalence, symptoms and outcome in 2017. Am J Emerg Med 36 : 464-466, 2018.
PubMed
7) 佐中孜 : 尿毒症患者における中分子物質に関する研究. 日本腎臓学会誌 20 : 593-610, 1978.
 
8) Wood JE, Mahnensmith RL : Pericarditis associated with renal failure : evolution and management. Semin Dial 14 : 61-66, 2001.
PubMed
9) Marini PV, Hull AR : Uremic pericarditis : a review of incidence and management. Kidney Int Suppl (2) : 163-166, 1975.
PubMed
10) Yoshida K, et al : Uremic pericardial effusion : detection and evaluation of uremic pericardial effusion by echocardiography. Clin Nephrol 13 : 260-268, 1980.
PubMed
11) Rehman KA, et al : Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease : Insights and pathophysiology. Clin Cardiol 40 : 839-846, 2017.
PubMed
12) Roberts WC : Pericardial heart disease : its morphologic features and its causes. Proc (Bayl Univ Med Cent) 18 : 38-55, 2005.
PubMed
13) Kumar S, Lesch M : Pericarditis in renal disease. Prog Cardiovasc Dis 22 : 357-369, 1980.
PubMed
14) Spodick DH : Electrocardiogram in acute pericarditis. Distributions of morphologic and axial changes by stages. Am J Cardiol 33 : 470-474, 1974.
PubMed
15) Rostand SG, Rutsky EA : Pericarditis in end-stage renal disease. Cardiol Clin 8 : 701-707, 1990.
PubMed
16) De Pace NL, et al : Predicting success of intensive dialysis in the treatment of uremic pericarditis. Am J Med 76 : 38-46, 1984.
PubMed
17) Quigg RJ, et al : Local steroids in dialysis-associated pericardial effusion. A single intrapericardial administration of triamcinolone. Arch Intern Med 145 : 2249-2250, 1985.
PubMed
18) Leehey DJ, et al : Predicting need for surgical drainage of pericardial effusion in patients with end-stage renal disease. Int J Artif Organs 12 : 618-625, 1989.
PubMed
19) Sagrista-Sauleda J, et al : Long-term follow-up of idiopathic chronic pericardial effusion. N Engl J Med 341 : 2054-2059, 1999.
PubMed
P.70 掲載の参考文献
1) Fraser CL, Arieff AI : Nervous system complications in uremia. Ann Intern Med 109 : 143-153, 1988.
PubMed
2) Burn DJ, Bates D : Neurology and the kidney. J Neurol Neurosurg Psychiatry 65 : 810-821, 1998.
PubMed
3) Hosoya K, Tachikawa M : Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15 : 478-485, 2011.
PubMed
4) Bolton CF, Young GB (ed) : Uremic encephalopathy. In : Neurological Complications of Renal Disease, p44, Butterworths, Boston, 1990.
 
5) Smogorzewski MJ : Central nervous dysfunction in uremia. Am J Kidney Dis 38 : S122-128, 2001.
PubMed
6) Olano CG, et al : Uremic Encephalopathy. In : StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing, 2022.
 
7) Rosner MH, et al : Uremic encephalopathy. Kidney Int 101 : 227-241, 2022.
PubMed
8) 塚口眞砂 : 肝障害・腎障害に伴う意識障害. 内科 97 : 835-838, 2006.
 
9) Seifter JL, Samuels MA : Neurologic complication of chronic kidney disease. In : Comprehensive Nephrology, 4th edition, p985-986, Elsevier Inc, Missouri, 2010.
 
10) Brenner RP : The electroencephalogram in altered states of consciousness. Neurol Clin 3 : 615-631, 1985.
PubMed
11) Moe SM, Sprangue SM : Uremic encephalopathy. Clin Nephrol 42 : 251-256, 1994.
 
12) Malek M : Brain consequences of acute kidney injury : Focusing on the hippocampus. Kidney Res Clin Pract 37 : 315-322, 2018.
PubMed
13) Kim DM, et al : Uremic Encephalopathy : MR Imaging Findings and Clinical Correlation. AJNR Am J Neuroradiol 37 : 1604-1609, 2016.
PubMed
14) Narra RK : Lentiform fork sign in uraemic encephalopathy. BMJ Case Rep 14 : e245623, 2021.
PubMed
15) Geboers K, et al : Lentiform fork sign in a girl with uremic encephalopathy. Acta Neurol Belg 122 : 535-536, 2022.
 
16) Fernandes GC, et al : Teaching NeuroImages : the lentiform fork sign : an MRI pattern of metformin-associated encephalopathy. Neurology 84 : e15, 2015.
PubMed
17) Kumar G, Goyal MK : Lentiform Fork sign : a unique MRI picture. Is metabolic acidosis responsible? Clin Neurol Neurosurg 112 : 805-812, 2010.
PubMed
18) Tatsumoto N, et al : Reversible posterior leukoencephalopathy syndrome in a patient with severe uremic encephalopathy. Clin Nephrol 74 : 154-158, 2010.
 
19) Baumgaertel MW, et al : Neurologic complications of acute and chronic renal disease. Handb Clin Neurol 119 : 383-393, 2014.
PubMed
20) Bleck TP, et al : Neurologic complications of critical medical illnesses. Crit Care Med 21 : 98-103, 1993.
PubMed
21) Polito A, et al : Pattern of brain injury in the acute setting of human septic shock. Crit Care 17 : R204, 2013.
PubMed
22) Sharshar T, et al : Brain lesions in septic shock : a magnetic resonance imaging study. Intensive Care Med 33 : 798-806, 2007.
PubMed
23) Lu R, et al : Kidney-brain crosstalk in the acute and chronic setting. Nat Rev Nephrol 11 : 707-719, 2015.
PubMed
24) Pantham G, Mullen KD : Practical Issues in the Management of Overt Hepatic Encephalopathy. Gastroenterol Hepatol (NY) 13 : 659-665, 2017.
 
25) Abe M, Kalantar-Zadeh K : Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol 11 : 302-313, 2015.
PubMed
26) Lumlertgul N, et al : Clearance of micronutrients during continuous renal replacement therapy. Crit Care 24 : 616, 2020.
PubMed
27) Zhang F, et al : The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. Kidney Int 90 : 396-403, 2016.
PubMed
28) Te Linde E, et al : Cognitive Function and Uremic Toxins after Kidney Transplantation : An Exploratory Study. Kidney360 1 : 1398-1406, 2020.
PubMed
P.74 掲載の参考文献
1) 舛本祥一, ほか : 原因不明の胸水貯留を繰り返し, 剖検にて尿毒症性胸膜炎と診断し得た維持透析患者の1例. 日本透析医学会雑誌 42 : 973-978, 2009.
 
2) Faubel S : Pulmonary complications after acute kidney injury. Adv Chronic Kidney Dis 15 : 284-296, 2008.
PubMed
3) Jarratt MJ, et al : Pleural effusions in hospitalized patients receiving long-term hemodialysis. Chest 108 : 470-474, 1995.
PubMed
4) Berger HW, et al : Uremic pleural effusion. A study in 14 patients on chronic dialysis. Ann Intern Med 82 : 362-364, 1975.
PubMed
5) 木藤知佳志, ほか : Dialysis ascitesが先行した後, 比較的短期間に血性胸水の発現をみた1透析例. 日本内科学会雑誌 75 : 1661-1662, 1986.
 
6) Bakirci T, et al : Pleural effusion in long-term hemodialysis patients. Transplant Proc 39 : 889-891, 2007.
PubMed
7) Bleyl U, et al : The pathology and biology of uremic pneumonitis. Intensive Care Med 7 : 193-202, 1981.
PubMed
8) Hopps HC, Wissler RW : Uremic pneumonitis. Am J Pathol 31 : 261-273, 1955.
PubMed
9) Hoke TS, et al : Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol 18 : 155-164, 2007.
PubMed
10) Ishii T, et al : Neutrophil elastase contributes to acute lung injury induced by bilateral nephrectomy. Am J Pathol 177 : 1665-1673, 2010.
PubMed
11) Klein CL, et al : Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 74 : 901-909, 2008.
PubMed
12) Chiang CS, et al : Neopterin, soluble interleukin-2 receptor and adenosine deaminase levels in pleural effusions. Respiration 61 : 150-154, 1994.
PubMed
13) 日ノ下文彦 : 結核-対策と最近の話題. 透析療法ネクスト VIII 感染対策 (秋葉隆, 秋澤忠男編), p74-83, 医学図書出版, 2009.
 
14) Inoue T, et al : The value of QuantiFERON TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant 24 : 2252-2257, 2009.
PubMed
15) Rodelas R, et al : Fibrosing uremic pleuritis during hemodialysis. JAMA 243 : 2424-2425, 1980.
PubMed
16) Yoshii C, et al : Bilateral massive pleural effusions caused by uremic pleuritis. Intern Med 40 : 646-649, 2001.
PubMed
17) 友田恒一, ほか : 血液透析に濾過を併用することにより軽快した尿毒症性胸膜炎の1例. 日本胸部臨床 51 : 249-253, 1992.
 
18) Iyoda M, et al : A case of refractory uremic pleuropericarditis - successful corticosteroid treatment. Clin Nephrol 65 : 290-293, 2006.
PubMed

XI 急性腎障害の病態

P.81 掲載の参考文献
1) Ishikawa I : Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia. Nephron 91 : 559-570, 2002.
PubMed
2) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
3) Matsuo H, et al : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83 : 744-751, 2008.
PubMed
4) 石川勲 : 運動後の急性腎障害. 日本内科学会雑誌 103 : 1101-1107, 2014.
 
5) Shima Y, et al : Recurrent EIARF and PRES with severe renal hypouricemia by compound heterozygous SLC2A9 mutation. Pediatrics 127 : e1621-1625, 2011.
PubMed
6) Fujinaga S, et al : Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur J Pediatr 172 : 1557-1560, 2013.
 
7) Kaneko K, et al : Oxidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol 24 : 869-871, 2009.
PubMed
8) 腎性低尿酸血症診療ガイドライン (厚生労働科学研究費補助金 (難治性疾患政策研究事業) : 腎・泌尿器系の希少・難治性疾患群に関する診断基準・診療ガイドラインの確立研究班 (腎性低尿酸血症担当), 日本痛風・核酸代謝学会共同編集), メディカルレビュー社, 2017.
 
P.85 掲載の参考文献
1) Kanjanabuch T, et al : An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 5 : 259-269, 2009.
PubMed
2) Ayoob RM, Schwaderer AL : Acute Kidney Injury and Atypical Features during Pediatric Poststreptococcal Glomerulonephritis. Int J Nephrol 2016 : 5163065, 2016.
PubMed
3) Usui J, et al : Temporal Changes in Post-Infectious Glomerulonephritis in Japan (1976-2009). PLoS One 11 : e0157356, 2016.
PubMed
4) Smith JD, Hayslett JP : Reversible renal failure in the nephrotic syndrome. Am J Kidney Dis 19 : 201-213, 1992.
 
5) Lu H, et al : Acute kidney injury in patients with primary nephrotic syndrome : influencing factors and coping strategies. BMC Nephrol 23 : 90, 2022.
PubMed
6) Meyrier A, Niaudet P : Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 94 : 861-869, 2018.
PubMed
7) Waldman M, et al : Adult minimal-change disease : clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2 : 445-453, 2007.
PubMed
8) Komukai D, et al : Influence of acute kidney injury on the time to complete remission in adult minimal change nephrotic syndrome : a single-centre study. Nephrology (Carlton) 21 : 887-892, 2016.
PubMed
9) Kagawa TF, et al : Crystal structure of the zymogen form of the group A Streptococcus virulence factor SpeB : an integrin-binding cysteine protease. Proc Natl Acad Sci U S A 97 : 2235-2240, 2000.
 
10) Yoshizawa N, et al : Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis : characterization of the antigen and associated immune response. J Am Soc Nephrol 15 : 1785-1793, 2004.
PubMed
11) Lowenstein J, et al : Renal failure in minimal change nephrotic syndrome. Am J Med 70 : 227-233, 1981.
PubMed
12) Cameron MA, et al : Minimal change disease with acute renal failure : a case against the nephrosarca hypothesis. Nephrol Dial Transplant 19 : 2642-2646, 2004.
 
13) Colombo PC, et al : Endothelial cell activation in patients with decompensated heart failure. Circulation 111 : 58-62, 2005.
PubMed
14) Colombo PC, et al : Inflammatory activation : cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17 : 177-190, 2012.
PubMed
15) Mullens W, et al : Elevated intra-abdominal pressure in acute decompensated heart failure : a potential contributor to worsening renal function? J Am Coll Cardiol 51 : 300-306, 2008.
PubMed
16) Ding X, et al : Intravenous Fluids and Acute Kidney Injury. Blood Purif 43 : 163-172, 2017.
PubMed
17) Chen CL, et al : Increased endothelin 1 expression in adult-onset minimal change nephropathy with acute renal failure. Am J Kidney Dis 45 : 818-825, 2005.
PubMed
18) Bohman SO, et al : Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome. Kidney Int 25 : 696-700, 1984.
PubMed
19) Fukasawa H, et al : Slit diaphragms contain tight junction proteins. J Am Soc Nephrol 20 : 1491-1503, 2009.
PubMed
20) Lyons H, et al : Allergic interstitial nephritis causing reversible renal failure in four patients with idiopathic nephrotic syndrome. N Engl J Med 288 : 124-128, 1973.
PubMed
21) Merida E, Praga M : NSAIDs and Nephrotic Syndrome. Clin J Am Soc Nephrol 14 : 1280-1282, 2019.
PubMed
22) Naesens M, et al : Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4 : 481-508, 2009.
PubMed
23) Kerlin BA, et al : Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol 29 : 989-997, 2014.
PubMed
P.91 掲載の参考文献
1) 解説11 妊娠関連急性腎障害 (AKI) の評価と周産期管理. 妊娠高血圧症候群の診療指針 2021-Best Practice Guide- (日本妊娠高血圧学会編), p163-166, メジカルビュー, 2021.
 
2) Mehrabadi A, et al : Investigation of a Rise in Obstetric Acute Renal Failure in the United States, 1999-2011. Obstet Gynecol 127 : 899-906, 2016.
PubMed
3) Shah S, et al : Pregnancy-Related Acute Kidney Injury in the United States : Clinical Outcomes and Health Care Utilization. Am J Nephrol 51 : 216-226, 2020.
PubMed
4) Dunlop W : Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 88 : 1-9, 1981.
PubMed
5) Lindheimer MD, et al : The kidney and hypertension in pregnancy : twenty exciting years. Semin Nephrol 21 : 173-189, 2001.
PubMed
6) Higby K, et al : Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 171 : 984-989, 1994.
PubMed
7) Makihara N, et al : A dipstick test combined with urine specific gravity improved the accuracy of proteinuria determination in pregnancy screening. Kobe J Med Sci 56 : E165-172, 2011.
PubMed
8) Brown MA, et al : The classification and diagnosis of the hypertensive disorders of pregnancy : statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20 : IX-XIV, 2001.
 
9) Szczepanski J, et al : Acute Kidney Injury in Pregnancies Complicated With Preeclampsia or HELLP Syndrome. Front Med (Lausanne) 7 : 22, 2020.
PubMed
10) Liu Y, et al : Pregnancy outcomes in patients with acute kidney injury during pregnancy : a systematic review and meta-analysis. BMC Pregnancy Childbirth 17 : 235, 2017.
PubMed
11) Gul A, et al : Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure. Ren Fail 26 : 557-562, 2004.
PubMed
12) Conti-Ramsden FI, et al : Pregnancy-Related Acute Kidney Injury in Preeclampsia : Risk Factors and Renal Outcomes. Hypertension 74 : 1144-1151, 2019.
PubMed
13) Hinchey J, et al : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 : 494-500, 1996.
 
14) Mattar F, Sibai BM Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 182 : 307-312, 2000.
PubMed
15) Sibai BM, et al : Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169 : 1000-1006, 1993.
PubMed
16) Kobayashi T, et al : Anticholinergics induce eclamptic seizures. Semin Thromb Hemost 28 : 511-514, 2002.
PubMed
17) Selcuk NY, et al : Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989-1999). Ren Fail 22 : 319-327, 2000.
PubMed
18) 解説16 妊産婦脳卒中. 妊娠高血圧症候群の診療指針 2021-Best Practice Guide- (日本妊娠高血圧学会編), p186-190, メジカルビュー, 2021.
 
19) 難病情報センター : 非典型溶血性尿毒症症候群 (指定難病109) 概要・診断基準等 (厚生労働省作成). [https://www.nanbyou.or.jp/entry/3847]
 
20) Fakhouri F, et al : Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21 : 859-867, 2010.
PubMed
21) Taber-Hight E, Shah S : Acute Kidney Injury in Pregnancy. Adv Chronic Kidney Dis 27 : 455-460, 2020.
PubMed
22) Wind M, et al : Therapeutic plasma exchange in pregnancy : A literature review. Eur J Obstet Gynecol Reprod Biol 260 : 29-36, 2021.
PubMed
23) Bellig LL : Maternal acute fatty liver of pregnancy and the associated risk for long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency in infants. Adv Neonatal Care 4 : 26-32, 2004.
PubMed
24) Meng Z, et al : Risk Factors for Maternal and Fetal Mortality in Acute Fatty Liver of Pregnancy and New Predictive Models. Front Med (Lausanne) 8 : 719906, 2021.
 
25) Brandes JC, Fritsche C : Obstructive acute renal failure by a gravid uterus : a case report and review. Am J Kidney Dis 18 : 398-401, 1991.
PubMed
26) Thol FR, Popp G : When childbirth causes reversed hemodialysis and renal failure. South Med J 102 : 306-307, 2009.
PubMed
P.97 掲載の参考文献
1) Pearse RM, et al : Mortality after surgery in Europe : a 7 day cohort study. Lancet 380 : 1059-1065, 2012.
PubMed
2) Basile DP, et al : Progression after AKI : Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. J Am Soc Nephrol 27 : 687-697, 2016.
PubMed
3) KDIGO Acute Kidney Injury Work Group : KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2 : 1-138, 2012.
 
4) Zarbock A, et al : Update on Perioperative Acute Kidney Injury. Anesth Analg 127 : 1236-1245, 2018.
PubMed
5) Prowle JR, et al : Postoperative acute kidney injury in adult non-cardiac surgery : joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol 17 : 605-618, 2021.
PubMed
6) Uchino S, et al : Acute renal failure in critically ill patients : a multinational, multicenter study. JAMA 294 : 813-818, 2005.
PubMed
7) Wang Y, Bellomo R : Cardiac surgery-associated acute kidney injury : risk factors, pathophysiology and treatment. Nat Rev Nephrol 13 : 697-711, 2017.
PubMed
8) Hu J, et al : Global Incidence and Outcomes of Adult Patients With Acute Kidney Injury After Cardiac Surgery : A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth 30 : 82-89, 2016.
PubMed
9) Boyer N, et al : Postoperative AKI. Clin J Am Soc Nephrol 17 : 1535-1545, 2022.
PubMed
10) Ostermann M, Liu K : Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol 31 : 305-314, 2017.
PubMed
11) Saadat-Gilani K, et al : Perioperative Renoprotection : Clinical Implications. Anesth Analg 131 : 1667-1678, 2020.
PubMed
12) Meersch M, et al : Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers : the PrevAKI randomized controlled trial. Intensive Care Med 43 : 1551-1561, 2017.
PubMed
13) Sun LY, et al : Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology 123 : 515-523, 2015.
PubMed
14) Jessen MK, et al : Goal-directed haemodynamic therapy during general anaesthesia for noncardiac surgery : a systematic review and meta-analysis. Br J Anaesth 128 : 416-433, 2022.
PubMed
15) Gumbert SD, et al : Perioperative Acute Kidney Injury. Anesthesiology 132 : 180-204, 2020.
PubMed
16) Myburgh JA, et al : Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 : 1901-1911, 2012.
 
17) Gordon AC, et al : The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36 : 83-91, 2010.
PubMed
P.103 掲載の参考文献
1) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Supple 2 : 1-138, 2012.
 
2) AKI (急性腎障害) 診療ガイドライン 2016 (AKI (急性腎障害) 診療ガイドライン作成委員会編), 日本腎臓学会誌 59 : 419-533, 2017.
 
3) Moreno R, et al : The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 25 : 686-696, 1999.
 
4) Singer M, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
PubMed
5) Sawhney S, et al : Long-term prognosis after acute kidney injury (AKI) : what is the role of baseline kidney function and recovery? A systematic review. BMJ Open 5 : e006497, 2015.
PubMed
6) Susantitaphong P, et al : World incidence of AKI : a meta-analysis. Clin J Am Soc Nephrol 8 : 1482-1493, 2013.
 
7) Yasuda H, et al : Incidence and clinical outcomes of acute kidney injury requiring renal replacement therapy in Japan. Ther Apher Dial 14 : 541-546, 2010.
PubMed
8) Miyamoto Y, et al : Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units : analysis of a nationwide administrative database in Japan, 2007-2016. Crit Care 23 : 172, 2019.
PubMed
9) Langenberg C, et al : Renal blood flow in sepsis. Crit Care 9 : R363-374, 2005.
PubMed
10) Bellomo R, et al : Septic acute kidney injury : new concepts. Nephron Exp Nephrol 109 : e95-100, 2008.
PubMed
11) Rosen S, Stillman IE : Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J Am Soc Nephrol 19 : 871-875, 2008.
 
12) Abuelo JG : Normotensive ischemic acute renal failure. N Engl J Med 357 : 797-805, 2007.
PubMed
13) Doi K : The need for disruptive innovation in acute kidney injury. Clin Exp Nephrol 24 : 979-988, 2020.
PubMed
14) Aomatsu A, et al : MicroRNA expression profiling in acute kidney injury. Transl Res 244 : 1-31, 2022.
PubMed
15) See E, et al : The future of continuous renal replacement therapy. Semin Dial 34 : 576-585, 2021.
PubMed
P.107 掲載の参考文献
1) Jung DC, et al : Renal papillary necrosis : review and comparison of findings at multi-detector row CT and intravenous urography. Radiographics 26 : 1827-1836, 2006.
PubMed
2) Mandel EE : Renal medullary necrosis. Am J Med 13 : 322-327, 1952.
PubMed
3) Simon HB, et al : Renal papillary necrosis : a clinicopathologic study of 42 cases. J Urol 77 : 557-567, 1957.
 
4) Bach PH, Nguyen TK : Renal papillary necrosis - 40 years on. Toxicol Pathol 26 : 73-91, 1998.
PubMed
5) Rocha GM, et al : Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. Proc Natl Acad Sci U S A 98 : 5317-5322, 2001.
PubMed
6) Isnard Bagnis C, et al : Herbs and the kidney. Am J Kidney Dis 44 : 1-11, 2004.
PubMed
7) Jung DC, et al : Renal papillary necrosis : review and comparison of findings at multi-detector row CT and intravenous urography. Radiographics 26 : 1827-1836, 2006.
PubMed
8) Brix AE : Renal papillary necrosis. Toxicol Pathol 30 : 672-674, 2002.
PubMed
9) Burry A : Pathology of analgesic nephropathy : Australian experience. Kidney Int 13 : 34-40, 1978.
PubMed
10) Vijayaraghavan SB, et al : Sonographic features of necrosed renal papillae causing hydronephrosis. J Ultrasound Med 22 : 951-956 ; quiz 957-958, 2003.
 
11) Lang EK, et al : Detection of medullary and papillary necrosis at an early stage by multiphasic helical computerized tomography. J Urol 170 : 94-98, 2003.
PubMed
P.110 掲載の参考文献
1) Prakash J, et al : Decreasing incidence of renal cortical necrosis in patients with acute renal failure in developing countries : a single-centre experience of 22 years from Eastern India. Nephrol Dial Transplant 22 : 1213-1217, 2007.
PubMed
2) Lim LM, et al : Anuric acute renal failure after elective abortion. Intern Med 50 : 1715-1718, 2011.
PubMed
3) Ali A, et al : Hospital outcomes of obstetrical-related acute renal failure in a tertiary care teaching hospital. Ren Fail 33 : 285-290, 2011.
 
4) Kleinknecht D, et al : Diagnostic procedures and long-term prognosis in bilateral renal cortical necrosis. Kidney Int 4 : 390-400, 1973.
PubMed
5) Sheehan HL, Moore HC : Renal Cortical Necrosis and the Kidney of Concealed Accidental Haemorrhage, p183-p200, Blackwell Scientific Publications, Oxford, 1952.
 
6) Hashimoto S, et al : Unilateral renal cortical necrosis with contralateral hydronephrosis after surgery for uterus carcinoma. Clin Exp Nephrol 7 : 72-76, 2003.
PubMed
7) Kim HJ, Cho OK : CT scan as an important diagnostic tool in the initial phase of diffuse bilateral renal cortical necrosis. Clin Nephrol 45 : 125-130, 1996.
PubMed
8) Prasad CB, et al : Acute renal cortical necrosis : cortical rim sign and reverse rim sign. Kidney Int 100 : 1146, 2021.
PubMed
9) Francois M, et al : MR imaging features of acute bilateral renal cortical necrosis. Am J Kidney Dis 35 : 745-748, 2000.
PubMed
10) Jeong JY, et al : MR findings of renal cortical necrosis. J Comput Assist Tomogr 26 : 232-236, 2002.
PubMed

XII 維持透析患者にみられる病態

P.118 掲載の参考文献
1) Edwards SR, Unger AM : Acute hydrothorax-a new complication of peritoneal dialysis. JAMA 199 : 853-855, 1967.
PubMed
2) Chow KM, et al : Management options for hydrothorax complicating peritoneal dialysis. Semin Dial 16 : 389-394, 2003.
PubMed
3) 池田祥子, ほか : 腹膜透析施行中に左側多量胸水を認め, 99mTc-Sn-colloid scintigraphyを用いて横隔膜交通症と診断した1例. 日本透析医学会雑誌 40 : 877-881, 2007.
 
4) Nomoto Y, et al : Acute hydrothorax in continuous ambulatory peritoneal dialysis-a collaborative study of 161 centers. Am J Nephrol 9 : 363-367, 1989.
PubMed
5) Sharma A, Blake PG : Peritoneal dialysis. In : Brenner and Rector's The Kidney, 8th ed (ed by Brenner BM), p2007-2036, Saunders Elsevier Inc, Philadelphia, 2008.
 
6) Bargman JM : Complications of peritoneal dialysis related to increased intraabdominal pressure. Kidney Int Suppl 40 : S75-S80, 1993.
PubMed
7) 高橋義人, ほか : 胸水合併のためCAPD療法を断念した1例. 日本透析療法学会雑誌 23 : 1387-1393, 1990.
 
8) Yves RS, et al : Management of a massive hydrothorax in a CAPD patient : A case report and a review of the literature. Perit Dial Int 2 : 69-72, 1982.
 
9) Lepage S, et al : Massive hydrothorax complicating peritoneal dialysis. Isotopic investigation (peritoneopleural scintigraphy). Clin Nucl Med 18 : 498-501, 1993.
PubMed
10) 岡田一義, ほか : 自家血注入による胸膜癒着術を試みたCAPD横隔膜交通症の1例. 日本透析医学会雑誌 24 : 75-78, 1991.
 
11) 尾形聡, ほか : 一時的中断によりCAPDを続行しえたCAPD横隔膜交通症の1例. 臨牀透析 16 : 801-804, 2000.
 
12) 大高亮彦, ほか : CAPD を継続しながら胸膜癒着術を行ったCAPD横隔膜交通症の1例. 日本透析医学会雑誌 26 : 1332-1336, 1993.
 
13) 浜田真, ほか : 著明な胸水貯留を合併したCAPDの1例. 腎と透析 19 : 249-252, 1985.
 
14) Pattison CW, et al : Surgical treatment of hydrothorax complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 21 : 191-193, 1984.
PubMed
15) Bisceglie MD, et al : Videothoracoscopic obliteration of pleuroperitoneal fistula in continuous peritoneal dialysis. Am Thorac Surg 62 : 1509-1510, 1996.
 
16) 宍戸崇, ほか : 胸腔鏡下手術後に横隔膜交通症の再発を認めたCAPD患者の1例-本邦における報告例のまとめ-. 日本透析医学会雑誌 43 : 873-879, 2010.
 
P.123 掲載の参考文献
1) 第6章 腹膜炎管理. 日本透析医学会ブックシリーズ 1 : 腹膜透析ガイドライン 2019 (腹膜透析ガイドライン改訂ワーキンググループ編), 一般社団法人日本透析医学会, 2019.
 
2) Li PK, et al : ISPD peritonitis guideline recommendations : 2022 update on prevention and treatment. Perit Dial Int 42 : 110-153, 2022.
PubMed
3) Szeto CC, et al : Peritoneal Dialysis-Associated Peritonitis. Clin J Am Soc Nephrol 14 : 1100-1105, 2019.
PubMed
4) Mizuno M, et al : Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin Exp Nephrol 15 : 727-737, 2011.
PubMed
5) Mizuno M, et al : Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan : the second report of the Tokai peritoneal dialysis registry. Clin Exp Nephrol 20 : 960-971, 2016.
PubMed
6) Tawada M, et al : Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients. PLoS One 11 : e0154644, 2016.
PubMed
7) Tawada M, et al : Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions. Nephrol Dial Transplant 36 : 1519-1526, 2021.
PubMed
P.127 掲載の参考文献
1) Bunke M, et al : Pseudomonas peritonitis in peritoneal dialysis patients : the Network #9 Peritonitis Study. Am J Kidney Dis 25 : 769-774, 1995.
 
2) Adekambi T : Mycobacterium mucogenicum group infections : a review. Clin Microbiol Infect 15 : 911-918, 2009.
PubMed
3) Warady BA, et al : Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 20 : 610-624, 2000.
PubMed
4) Szeto CC, et al : ISPD Catheter-Related Infection Recommendations : 2017 Update. Perit Dial Int 37 : 141-154, 2017.
PubMed
5) 腹膜透析ガイドライン 2019 (日本透析医学会腹膜透析ガイドライン改訂ワーキンググループ編). 医学図書出版, 2019.
 
6) Crabtree JH, Burchette RJ : Surgical salvage of peritoneal dialysis catheters from chronic exit-site and tunnel infections. Am J Surg 190 : 4-8, 2005.
PubMed
7) Yoshino A, et al : Merit of the cuff-shaving procedure in children with chronic infection. Pediatr Nephrol 19 : 1267-1272, 2004.
 
8) Terawaki H, et al : Unroofing surgery with en bloc resection of the skin and tissues around the peripheral cuff. Perit Dial Int 33 : 573-576, 2013.
PubMed
9) Boudville N, et al : Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 34 : 2118-2126, 2019.
PubMed
10) Liu WJ, Hooi LS : Complications after tenckhoff catheter insertion : a single-centre experience using multiple operators over four years. Perit Dial Int 30 : 509-512, 2010.
PubMed
11) Johnson DW, et al : A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients. Am J Kidney Dis 48 : 812-821, 2006.
PubMed
12) 深澤瑞也, ほか : 新規挿入時に行う腹膜透析カテーテルの腹壁固定術 (New PWAT) PDカテーテル位置異常予防法. 日本透析医学会雑誌 39 : 235-242, 2006.
 
P.134 掲載の参考文献
1) Kawaguchi Y, et al : Encapsulating peritoneal sclerosis : definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20 (Suppl 4) : S43-55, 2000.
 
2) Gandhi VC, et al : Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140 : 1201-1203, 1980.
PubMed
3) Kawanishi H, et al : Encapsulating peritoneal sclerosis in Japan : a prospective, controlled, multicenter study. Am J Kidney Dis 44 : 729-737, 2004.
PubMed
4) Petrie MC, et al : Incidence and outcome of encapsulating peritoneal sclerosis. Clin Kidney J 9 : 624-629, 2016.
PubMed
5) Nakayama M, et al : Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions : the NEXT-PD study. Perit Dial Int 34 : 766-774, 2014.
PubMed
6) Johnson DW, et al : Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 23 : 1097-1107, 2012.
PubMed
7) Kawanishi K, et al : Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int 33 : 242-251, 2013.
PubMed
8) Hamada C, et al : Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs 18 : 243-250, 2015.
PubMed
9) Moriishi M, et al : Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 18 : 149-153, 2002.
PubMed
10) Yamamoto T, et al : The role of peritoneal lavage and the prognostic significance of mesothelial cell area in preventing encapsulating peritoneal sclerosis. Perit Dial Int 30 : 343-352, 2010.
PubMed
11) Habib SM, et al : Management of encapsulating peritoneal sclerosis : a guideline on optimal and uniform treatment. Neth J Med 69 : 500-507, 2011.
PubMed
12) Loureiro J, et al : Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One 8 : e61165, 2013.
PubMed
13) Korte MR, et al : Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis : results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 26 : 691-697, 2011.
PubMed
14) Woodrow G, et al : Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children. BMC Nephrol 18 : 333, 2017.
PubMed
15) Kawanishi H, et al : Surgical Treatment for Encapsulating Peritoneal Sclerosis : 24 Years' Experience. Perit Dial Int 39 : 169-174, 2019.
PubMed
P.139 掲載の参考文献
1) Selye H, et al : Cutaneous molt induced by calciphylaxis in the rat. Science 134 : 1876-1877, 1961.
PubMed
2) 林松彦, ほか : 全国調査に基づくカルシフィラキシス診断基準の提案. 日本透析医学会雑誌 45 : 551-557, 2012.
 
3) Udomkarnjananun S, et al : Treatment of Calciphylaxis in CKD : A Systematic Review and Meta-analysis. Kidney Int Rep 4 : 231-244, 2019.
PubMed
4) Nigwekar SU, et al : Calciphylaxis : risk factors, diagnosis, and treatment. Am J Kidney Dis 66 : 133-146, 2015.
PubMed
5) Lee JL, et al : Recognizing calcific uremic arteriolopathy in autoimmune disease : an emerging mimicker of vasculitis. Autoimmun Rev 7 : 638-643, 2008.
PubMed
6) Danziger J : Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 3 : 1504-1510, 2008.
PubMed
7) Schafer C, et al : The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 : 357-366, 2013.
 
8) 林松彦 : カルシフィラキシスの診断と治療. 日本透析医会雑誌 29 : 252-255, 2014.
 
9) Basile C, et al : Hyperbaric oxygen therapy for calcific uremic arteriolopathy : a case series. J Nephrol 15 : 676-680, 2002.
 
10) Ackermann F, et al : Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 143 : 1336-1337 ; author reply 1338, 2007.
PubMed
11) Nigwekar SU, et al : Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8 : 1162-1170, 2013.
PubMed
P.146 掲載の参考文献
1) Palmer S, et al : Prevalence of depression in chronic kidney disease : systematic review and meta-analysis of observational studies. Kidney Int 84 : 179-191, 2013.
PubMed
2) Lopes AA, et al : Screening for depression in hemodialysis patients : associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 66 : 2047-2053, 2004.
PubMed
3) 堀川直史 : 透析患者のうつ病. 日本透析医会雑誌 31 : 313-318, 2016.
 
4) Farrokhi F, et al : Association between depression and mortality in patients receiving long-term dialysis : a systematic review and meta-analysis. Am J Kidney Dis 63 : 623-635, 2014.
PubMed
5) Palmer SC, et al : Association between depression and health in people with CKD : a meta-analysis of cohort studies. Am J Kidney Dis 62 : 493-505, 2013.
 
6) Cukor D, et al : Anxiety disorders in adults treated by hemodialysis : a single-center study. Am J Kidney Dis 52 : 128-136, 2008.
PubMed
7) Murtagh FE, et al : The prevalence of symptoms in end-stage renal disease : a systematic review. Adv Chronic Kidney Dis 14 : 82-99, 2007.
PubMed
8) Kimmel PL, et al : Psychiatric illness and mortality in hospitalized ESKD patients. Clin J Am Soc Nephrol 14 : 1363-1371, 2019.
PubMed
9) Kosmadakis GC, Medcalf JF : Sleep disorders in dialysis patients. Int J Artif Organs 31 : 919-927, 2008.
PubMed
10) Pierratos A, Hanly PJ : Sleep disorders over the full range of chronic kidney disease. Blood Purif 31 : 146-150, 2011.
PubMed
11) 小池茂文 : 透析患者のむずむず脚症候群と睡眠障害. 全人力・科学力・透析力for the people透析医学 (平方秀樹監), p599-603, 医薬ジャーナル社, 2014.
 
12) Bognicourt JM, et al : Cognitive disorders and dementia in CKD : the neglected kidney-brain axis. J Am Soc Nephrol 24 : 353-363, 2013.
 
13) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 2010年12月31日現在. 日本透析医学会, 2011.
 
14) Sekita A, et al : Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community : the Hisamaya Study. Acta Psychiatr Scand 122 : 319-325, 2010.
 
15) Hedayati SS, Finkelstein FO : Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis 54 : 741-752, 2009.
PubMed
16) 堀川直史 : 透析患者のメンタルヘルス. 臨床透析 33 : 85-91, 2017.
 
17) 平田純生, 古久保拓 : 透析患者への投薬ガイドブック [改訂3版] 慢性腎臓病 (CKD) の薬物治療. じほう, 2017.
 
18) 春木繁一 : サイコネフロロジーの臨床-透析患者のこころを受け止める・支える, メディカ出版, 2010.
 
19) 堀川直史 : 腎不全 (特に透析) 患者に見られる精神症状とその治療的アプローチ. 臨床精神薬理 20 : 413-419, 2017.
 
20) Bargiel-Matusiewicz K, et al : The positive influence of psychological intervention on the level of anxiety and depression in dialysis patients : A pilot study. Int J Artif Organs 42 : 167-174, 2019.
PubMed
21) Valsaraj BP, et al : Cognitive behaviour therapy for anxiety and depression among people undergoing haemodialysis : as randomized controll trial. J Clin Diagn Res 10 : VC06-VC10, 2016.
 
P.151 掲載の参考文献
1) Weismann RE, Tobin RW : Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 76 : 219-225 ; discussion 225-227, 1958.
 
2) ヘパリン起因性血小板減少症の診断・治療ガイドライン. 日本血栓止血学会誌 32 : 737-782, 2021.
 
3) Yamamoto S, et al : Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28 : 82-85, 1996.
PubMed
4) Doi Y, et al : Heparin-induced thrombocytopenia among incident hemodialysis patients anticoagulated with low molecular weight heparin : A single-center retrospective study. Nefrologia (Engl Ed) 41 : 356-358, 2021.
 
5) Hutchison CA, Dasgupta I : National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22 : 1680-1684, 2007.
PubMed
6) Zheng Y, et al : Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 121 : 3484-3492, 2013.
 
7) Krauel K, et al : Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 117 : 1370-1378, 2011.
PubMed
8) Jaax ME, et al : Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 122 : 272-281, 2013.
PubMed
9) Bito S, et al : Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery. Blood 127 : 1036-1043, 2016.
PubMed
10) Zheng Y, et al : B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 123 : 931-934, 2014.
 
11) Warkentin TE, Kelton JG : Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 : 1286-1292, 2001.
PubMed
12) Maharaj S, et al : Temporality of heparin-induced antibodies : a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol 7 : 23, 2018.
PubMed
13) Cuker A, et al : Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia : a systematic review and meta-analysis. Blood 120 : 4160-4167, 2012.
PubMed
14) Sun L, et al : Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis. Thromb Haemost 115 : 1044-1055, 2016.
PubMed
15) Pouplard C, et al : Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5 : 1373-1379, 2007.
PubMed
P.153 掲載の参考文献
1) Lam JR, et al : Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology 152 : 821-829.e1, 2017.
 
2) Bazeley J, et al : C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 6 : 2452-2461, 2011.
PubMed
3) Karaboyas A, et al : Association between serum ferritin and mortality : findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 33 : 2234-2244, 2018.
PubMed
4) Hamano T, et al : Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 5 : 23-32, 2015.
PubMed
5) Isaacs JD, et al : Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther 15 : R204, 2013.
PubMed
6) Yamaguchi S, et al : Mean corpuscular hemoglobin concentration : an anemia parameter predicting cardiovascular disease in incident dialysis patients. J Nephrol 35 : 535-544, 2022.
PubMed
7) Niebauer J, et al : Endotoxin and immune activation in chronic heart failure : a prospective cohort study. Lancet 353 : 1838-1842, 1999.
PubMed
8) Nemeth E, et al : Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 : 2090-2093, 2004.
PubMed
9) Sasaki Y, et al : Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol 96 : 692-700, 2012.
 
10) Kakimoto-Shino M, et al : Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients : a randomized study. Ther Apher Dial 18 : 421-426, 2014.
PubMed
11) Shoji S, et al : Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 90 : 237-244, 2013.
 
12) Provenzano R, et al : Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis : A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am J Kidney Dis 67 : 912-924, 2016.
 
13) Pergola PE, et al : Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis : Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol 32 : 211-222, 2021.
 
P.159 掲載の参考文献
1) Moe S, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006.
PubMed
2) Kazama JJ, Fukagawa M : In and out of the bone : can the osteocyte escape skeletal jail and yet regulate mineralization? Kidney Int 85 : 11-12, 2014.
PubMed
3) Cannata-Andia JB, Rodriguez-Garcia M : Hyperphosphataemia as a cardiovascular risk factor-how to manage the problem. Nephrol Dial Transplant 17 (Suppl 11) : 16-19, 2002.
 
4) Raggi P, et al ; ADVANCE Study Group : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011.
 
5) Isaka Y, et al : Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. J Am Soc Nephrol 32 : 723-735, 2021.
PubMed
6) Anzai F, et al : Calciprotein Particles Induce IL-1β/α-Mediated Inflammation through NLRP3 Inflammasome-Dependent and -Independent Mechanisms. Immunohorizons 5 : 602-614, 2021.
 
7) Yamada S, et al : PiT-2, a type III sodium-dependent phosphate transporter, protects against vascular calcification in mice with chronic kidney disease fed a high-phosphate diet. Kidney Int 94 : 716-727, 2018.
PubMed
8) Jono S, et al : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000.
PubMed
9) Chen NX, et al : Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62 : 1724-1731, 2002.
PubMed
10) Shigematsu T, et al : Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant 18 (Suppl 3) : iii86-iii89, 2003.
 
11) London GM, et al : Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 : 1943-1951, 2004.
PubMed
12) Zhang K, et al : Effects of parathyroid hormone-related protein on osteogenic and adipogenic differentiation of human mesenchymal stem cells. Eur Rev Med Pharmacol Sci 18 : 1610-1617, 2014.
PubMed
13) Urena-Torres P, et al : Valvular heart disease and calcification in CKD : more common than appreciated. Nephrol Dial Transplant 35 : 2046-2053, 2020.
PubMed
14) Hayashi M, et al : A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27 : 1580-1584, 2012.
 
15) Kuro-O M : Phosphate as a Pathogen of Arteriosclerosis and Aging. J Atheroscler Thromb 28 : 203-213, 2021.
PubMed
P.165 掲載の参考文献
1) Sahathevan S, et al : Understanding development of malnutrition in hemodialysis patients : a narrative review. Nutrients 12 : 3147, 2020.
PubMed
2) Oliveira CM, et al : Correlation between nutritional markers and appetite self-assessments in hemodialysis patients. J Ren Nutr 25 : 301-307, 2015.
PubMed
3) Schwotzer N, et al : Water-Soluble Vitamin Levels and Supplementation in Chronic Online Hemodiafiltration Patients. Kidney Int Rep 5 : 2160-2167, 2020.
PubMed
4) Shimizu S, et al : Prevalence of zinc deficiency in Japanese patients on peritoneal dialysis : Comparative study in patients on hemodialysis. Nutrients 12 : 764, 2020.
PubMed
5) Mahajan SK, et al : Improvement of uremic hypogeusia by zinc : a double-blind study. Am J Clin Nutr 33 : 1517-1521, 1980.
PubMed
6) Garagarza C, et al : Zinc Deficient Intake in Hemodialysis Patients : A Path to a High Mortality Risk. J Ren Nutr 32 : 87-93, 2022.
 
7) de Mutsert R, et al : Subjective global assessment of nutritional status is strongly associated with mortality in chronic dialysis patients. Am J Clin Nutr 89 : 787-793, 2009.
PubMed
8) Ikizler TA, et al : KDOQI Clinical Practice Guideline for Nutrition in CKD : 2020 Update. Am J Kidney Dis 76 : S1-S107, 2020.
PubMed
9) Kalantar-Zadeh K, et al : A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38 : 1251-1263, 2001.
PubMed
10) Nakagawa N, et al : Utility of Geriatric Nutritional Risk Index in patients with chronic kidney disease : A mini-review. Nutrients 13 : 3688, 2021.
PubMed
11) Holvoet E, et al : The screening score of Mini Nutritional Assessment (MNA) is a useful routine screening tool for malnutrition risk in patients on maintenance dialysis. PLoS One 15 : e0229722, 2020.
PubMed
12) Sohrabi Z, et al : Comparison of the Nutritional Status Assessment Methods for Hemodialysis Patients. Clin Nutr Res 10 : 219-229, 2021.
PubMed
13) Fouque D, et al : A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 : 391-398, 2008.
PubMed
14) Kanda E, et al : A new nutritional risk index for predicting mortality in hemodialysis patients : Nationwide cohort study. PLoS One 14 : e0214524, 2019.
PubMed
15) Cederholm T, et al : GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community. Clin Nutr 38 : 1-9, 2019.
 
16) Avesani CM, et al : A comparative analysis of nutritional assessment using global leadership initiative on malnutrition versus subjective global assessment and malnutrition inflammation score in maintenance hemodialysis patients. J Ren Nutr 32 : 476-482, 2022.
PubMed
17) Song HC, et al : Utility of the Global Leadership Initiative on Malnutrition criteria for the nutritional assessment of patients with end-stage renal disease receiving chronic hemodialysis. J Hum Nutr Diet, 2022. (DOI : 10.1111/jhn.13019)
 
18) Notomi S, et al : Impact of cafeteria service discontinuation at a dialysis facility on medium-term nutritional status of elderly patients undergoing hemodialysis. Nutrients 14 : 1628, 2022.
 
19) Sabatino A, et al : Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr 36 : 663-671, 2017.
PubMed
20) Sahathevan S, et al : Clinical efficacy and feasibility of whey protein isolates supplementation in malnourished peritoneal dialysis patients : A multicenter, parallel, open-label randomized controlled trial. Clin Nutr ESPEN 25 : 68-77, 2018.
PubMed
21) Sohrabi Z, et al : Intradialytic Oral Protein Supplementation and Nutritional and Inflammation Outcomes in Hemodialysis : A Randomized Controlled Trial. Am J Kidney Dis 68 : 122-130, 2016.
PubMed
22) Cano NJ, et al : ESPEN Guidelines on Parenteral Nutrition : adult renal failure. Clin Nutr 28 : 401-414, 2009.
PubMed
P.170 掲載の参考文献
1) Trivedi H, et al : Gastrointestinal bleeding in patients on long-term dialysis. J Nephrol 28 : 235-243, 2015.
PubMed
2) Niikura R, et al : Natural history of upper and lower gastrointestinal bleeding in hemodialysis patients : A dual-center long-term cohort study. J Gastroenterol Hepatol 36 : 112-117, 2021.
PubMed
3) Itatsu T, et al : Eradication of Helicobacter pylori in hemodialysis patients. Ren Fail 29 : 97-102, 2007.
PubMed
4) Sahara S, et al : Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis : A Randomized Controlled Trial. Digestion 97 : 163-169, 2018.
 
P.174 掲載の参考文献
1) Wheeler DC, et al : Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis : the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc 3 : e001363, 2014.
 
2) Nauta ST, et al : Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease : evolution from the prethrombolysis to the percutaneous coronary intervention era. Kidney Int 84 : 353-358, 2013.
 
3) Iwasaki M, et al : Declining prevalence of coronary artery disease in incident dialysis patients over the past two decades. J Atheroscler Thromb 21 : 593-604, 2014.
PubMed
4) Asakawa T, et al : Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease. Atherosclerosis 240 : 535-543, 2015.
PubMed
5) Sosnov J, et al : Differential symptoms of acute myocardial infarction in patients with kidney disease : a community-wide perspective. Am J Kidney Dis 47 : 378-384, 2006.
PubMed
6) Shroff GR, et al : Trends in Discharge Claims for Acute Myocardial Infarction among Patients on Dialysis. J Am Soc Nephrol 28 : 1379-1383, 2017.
PubMed
7) Kono K, et al : Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 82 : 344-351, 2012.
PubMed
8) Thygesen K, et al : Third universal definition of myocardial infarction. Eur Heart J 33 : 2551-2567, 2012.
PubMed
9) Gupta S, et al : Type 2 versus type 1 myocardial infarction : a comparison of clinical characteristics and outcomes with a meta-analysis of observational studies. Cardiovasc Diagn Ther 7 : 348-358, 2017.
PubMed
10) Baron T, et al : Impact on Long-Term Mortality of Presence of Obstructive Coronary Artery Disease and Classification of Myocardial Infarction. Am J Med 129 : 398-406, 2016.
PubMed
11) Shah AS, et al : Sensitive troponin assay and the classification of myocardial infarction. Am J Med 128 : 493-501.e3, 2015.
 
12) Saaby L, et al : Mortality rate in type 2 myocardial infarction : observations from an unselected hospital cohort. Am J Med 127 : 295-302, 2014.
PubMed
13) Saaby L, et al : Classification of myocardial infarction : frequency and features of type 2 myocardial infarction. Am J Med 126 : 789-797, 2013.
PubMed
14) Sandoval Y, et al : Supply/demand type 2 myocardial infarction : should we be paying more attention? J Am Coll Cardiol 63 : 2079-2087, 2014.
PubMed
15) Baron T, et al : Type 2 myocardial infarction in clinical practice. Heart 101 : 101-106, 2015.
PubMed
16) Izumaru K, et al : Reduced Estimated GFR and Cardiac Remodeling : A Population-Based Autopsy Study. Am J Kidney Dis 74 : 373-381, 2019.
PubMed
17) Nishimura M, et al : Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 69 : 553-559, 2006.
PubMed
18) Levin A, et al : Left ventricular mass index increase in early renal disease : impact of decline in hemoglobin. Am J Kidney Dis 34 : 125-134, 1999.
PubMed
19) Shoji T, et al : Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 66 : 1212-1220, 2004.
PubMed
20) McIntyre CW, et al : Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3 : 19-26, 2008.
 
21) Breidthardt T, et al : Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol 7 : 1285-1292, 2012.
PubMed
22) Hirakata H, et al : Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 16 : 387-435, 2012.
PubMed
23) Moriya H, et al : Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. Clin J Am Soc Nephrol 3 : 416-422, 2008.
PubMed
24) Moriya H, et al : Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis. Nephrol Dial Transplant 22 : 1198-1204, 2007.
PubMed
25) Nishimura M, et al : Oral nicorandil for prevention of cardiac death in hemodialysis patients without obstructive coronary artery disease : a propensity-matched patient analysis. Nephron Clin Pract 119 : c301-309, 2011.
PubMed
26) Bangalore S, et al : Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med 382 : 1608-1618, 2020.
PubMed
P.179 掲載の参考文献
1) 市川一夫, 加賀達志 : 人工透析患者の眼科的合併症. 現代医学 38 : 37-44, 1990.
 
2) 浅野亮, 加賀達志 : 透析患者の眼科的疾患 (白内障・緑内障) と眼科連携のポイント. 日本透析医会雑誌 32 : 282-288, 2017.
 
3) 市川一夫 : 眼疾患. 腎と透析 69 (増刊号) : 101-103, 2010.
 
4) 緑内障診療ガイドライン [第5版] (日本緑内障学会緑内障診療ガイドライン改訂委員会). 日本眼科学会雑誌 126 : 85-177, 2022.
 
5) Levy J, et al : Intraocular pressure during haemodialysis : a review. Eye (Lond) 19 : 1249-1256, 2005.
 
6) Chen SH, et al : Changes in Intraocular Pressure During Hemodialysis : A Meta-analysis. J Glaucoma 30 : 866-873, 2021.
PubMed
7) William JH, et al : Keeping an eye on dialysis : the association of hemodialysis with intraocular hypertension. Clin Nephrol 84 : 307-310, 2015.
PubMed
8) 服部達也, ほか : 緑内障患者に対するオンラインHDFの有用性. 日本血液浄化技術学会雑誌 24 : 296-298, 2016.
Medical*Online
9) 天野泉 : 眼圧変化と透析方法. 臨牀透析 14 : 1801-1806, 1998.
 
P.183 掲載の参考文献
1) Atroshi I, et al : Prevalence of carpal tunnel syndrome in a general population. JAMA 282 : 153-158, 1999.
 
2) Mondelli M, et al : Carpal tunnel syndrome incidence in a general population. Neurology 58 : 289-294, 2002.
 
3) 下条文武, ほか : 透析アミロイドーシス. 腎臓 10 : 135-142, 1987.
 
4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2017年12月31日現在). 日本透析医学会雑誌 51 : 699-766, 2018.
 
5) Hatano M, et al : Dialysis-related carpal tunnel syndrome in the past 40 years. Clin Exp Nephrol 26 : 68-74, 2022.
PubMed
6) 山中芳亮, 酒井昭典 : 透析患者の手根管症候群の病態と治療. 関節外科 38 : 455-459, 2019.
Medical*Online
7) 喜多島出, ほか : 長期血液透析に伴う手根管症候群に対する屈筋腱アミロイド沈着の影響. 日本手外科学会雑誌 27 : 322-324, 2011.
 
8) 喜多島出, ほか : 長期血液透析患者の再発性手根管症候群に対する浅指屈筋腱抜去術の長期成績. 日本手外科学会雑誌 31 : 268-270, 2014.
 
9) 吉田綾, ほか : 複数回再発透析性手根管症候群に対する正中神経皮下移所術の中長期成績. 末梢神経 31 : 305, 2020.
Medical*Online
P.188 掲載の参考文献
1) Liang JA, et al : The association between malignancy and end-stage renal disease in Taiwan. Jpn J Clin Oncol 41 : 752-757, 2011.
PubMed
2) Ishikawa I : Present status of renal cell carcinoma in dialysis patients in Japan : questionnaire study in 2002. Nephron Clin Pract 97 : c11-16, 2004.
PubMed
3) Dunnill MS, et al : Acquired cystic disease of the kidneys : a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 30 : 868-877, 1977.
PubMed
4) 腎癌取扱い規約 [第5版] (日本泌尿器科学会, 日本病理学会, 日本医学放射線学会編), メディカルレビュー社, 2020.
 
5) Tickoo SK, et al : Spectrum of epithelial neoplasms in end-stage renal disease : an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30 : 141-153, 2006.
PubMed
6) Kondo T, et al : Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients : Central pathology results according to the 2016 WHO classification in a multi-institutional study. Pathol Int 68 : 543-549, 2018.
 
7) Grantham JJ : Acquired cystic kidney disease. Kidney Int 40 : 143-152, 1991.
PubMed
8) Ito F, et al : Mutagen accumulated in cyst fluid of acquired cystic disease of the kidney. Nephron 86 : 192-194, 2000.
PubMed
9) Ishihara H, et al : Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease. Cancer Sci 111 : 4276-4287, 2020.
PubMed
10) Kondo T, et al : Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease : a multi-institutional central pathology study. Pathology 53 : 720-727, 2021.
PubMed
11) Ferda J, et al : Computed tomography of renal cell carcinoma in patients with terminal renal impairment. Eur J Radiol 63 : 295-301, 2007.
PubMed
12) Ikezawa E, et al : Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease. Jpn J Clin Oncol 44 : 1096-1100, 2014.
PubMed
13) Palsdottir HB, et al : Incidental detection of renal cell carcinoma is an independent prognostic marker : results of a long-term, whole population study. J Urol 187 : 48-53, 2012.
PubMed
14) Sassa N, et al : Renal cell carcinomas in haemodialysis patients : does haemodialysis duration influence pathological cell types and prognosis? Nephrol Dial Transplant 26 : 1677-1682, 2011.
PubMed
15) Omae K, et al : Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int J Clin Oncol 21 : 126-132, 2016.
PubMed
P.194 掲載の参考文献
1) Gejyo F, et al : A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 129 : 701-706, 1985.
PubMed
2) 研究代表者山田正仁 : III 各論 [4] 透析アミロイドーシス. アミロイドーシス診療ガイドライン 2010 (厚生労働科学研究費補助金難治性疾患克服事業アミロイドーシスに関する調査研究班平成20～22年度総合研究報告書), p27-31, 2010.
 
3) Hoshino J, et al : A clinical staging score to measure the severity of dialysis-related amyloidosis. Clin Exp Nephrol 21 : 300-306, 2017.
PubMed
4) Jadoul M, et al : Histological prevalence of β2-microglobulin amyloidosis in hemodialysis : a prospective post-mortem study. Kidney Int 51 : 1928-1932, 1997.
 
5) 日本透析医学会 : わが国の慢性透析療法の現況 (2017年12月31日現在), 2017年末の慢性透析患者に関する集計, 第8章 手根管開放術の既往. p733, 2018. [https://docs.jsdt.or.jp/overview/file/2017/pdf/8.pdf]
 
6) Hashimoto S, et al : Prevalence and Risk Factors of Carpal Tunnel Syndrome in Japanese Aged 50 to 89 Years. J Hand Surg Asian Pac Vol 25 : 320-327, 2020.
PubMed
7) Marcinko TM, et al : Structural Heterogeneity in the Preamyloid Oligomers of β-2-Microglobulin. J Mol Biol 432 : 396-409, 2020.
 
8) Yamamoto S : Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease : focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016. Clin Exp Nephrol 23 : 151-157, 2019.
 
9) Nishi S, et al : Multicentre cross-sectional study for bone-articular lesions associated with dialysis related amyloidosis in Japan. Nephrology (Carlton) 23 : 640-645, 2018.
PubMed
10) Nakai S, et al : Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38 : S212-216, 2001.
PubMed
11) Gejyo F, et al : Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial 17 : 40-47, 2013.
 
12) Kuragano T, et al : Clinical Benefit of an Adsorptive Technique for Elderly Long-Term Hemodialysis Patients. Contrib Nephrol 198 : 94-102, 2019.
PubMed
13) 維持血液透析ガイドライン : 血液透析処方. 日本透析医学会雑誌 46 : 587-632, 2013.
 
P.199 掲載の参考文献
1) 花房規男, ほか : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
2) 吉藤歩, 竜崎崇和 : 腎代替療法のすべて透析患者の合併症感染症 (細菌・真菌). 腎と透析 92 (増刊号) : 184-189, 2022.
 
3) 竜崎崇和, 吉藤歩 : 血液透析患者と感染症. 日本医師会雑誌 148 : 439-442, 2019.
 
4) 原田孝司, 室谷典儀 : 第57回日本透析医学会ワークショップより「死因上位を占める感染症 : 実態と対策」. 日本透析医学会雑誌 46 : 167-169, 2013.
 
5) Wakasugi M, et al : High mortality rate of infectious diseases in dialysis patients : a comparison with the general population in Japan. Ther Apher Dial 16 : 226-231, 2012.
PubMed
6) Nguyen DB, et al : National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. Clin J Am Soc Nephrol 12 : 1139-1146, 2017.
PubMed
7) Skov Dalgaard L, et al : Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis : A Population-Based Cohort Study. PLoS One 10 : e0124547, 2015.
PubMed
8) Grothe C, et al : Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis : a systematic review and meta-analysis. BMC Nephrol 15 : 202, 2014.
PubMed
9) Yamashita K, et al : Urinary Tract Infection in Hemodialysis-Dependent End-Stage Renal Disease Patients. Res Rep Urol 14 : 7-15, 2022.
PubMed
10) Van de Velde-Kossmann KM : Recognizing Common Skin and Soft Tissue Infections in the Nephrology Clinic. Blood Purif 47 : 259-264, 2019.
PubMed
11) 佐々木公一, ほか : 維持透析患者における肺炎の起因菌および菌検出の因子の検討. 日本腎臓学会誌 56 : 524-531, 2014.
 
12) 中山均, ほか : 透析患者の呼吸器感染症 IV. 肺結核臨床透析 24 : 1135-1142, 2008.
 
13) 吉藤歩, 竜崎崇和 : 慢性腎臓病・透析合併症感染症抗結核薬. 腎と透析 91 (増刊号) : 457-462, 2021.
 
14) 木村眞規子, ほか : 血液透析導入期の潜在性結核に関する検討. 日本透析医学会雑誌 51 : 599-605, 2018.
 
15) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療指針. 結核 88 : 497-512, 2013.
Medical*Online
16) Shah M, Dorman SE : Latent Tuberculosis Infection. N Engl J Med 385 : 2271-2280, 2021.
PubMed
17) C型肝炎治療ガイドライン (第8版) (日本肝臓学会肝炎診療ガイドライン作成委員会編), 2020年7月. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/C_v8_20201005.pdf]
 
18) 日本透析医会・日本透析医学会・日本腎臓学会新型コロナウイルス感染対策合同委員会 : 「透析患者における累積の新型コロナウイルス感染者の登録数 (2022年8月19日) 」.
 
19) Kikuchi K, et al : Survival and predictive factors in dialysis patients with COVID-19 in Japan : a nationwide cohort study. Ren Replace Ther 7 : 59, 2021.
PubMed
20) Yoshifuji A, et al : Committee report : Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy. Ren Replace Ther 8 : 18, 2022.
PubMed
P.203 掲載の参考文献
1) Geiyo F, et al : Serum levels of beta 2-microgloblin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314 : 585-586, 1986.
 
2) 島田久基, 鈴木正司 : 透析合併症 : アミロイド症. 腎と透析 61 : 573-577, 2006.
 
3) Otsubo S, et al : Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24 : 1593-1598, 2009.
PubMed
4) 佐久間正人 : 長期慢性透析患者の透析関連肩関節症の病態と成因について. 愛知医科大学医学会雑誌 23 : 565-572, 1995.
 
5) 橋詰博行, ほか : 透析肩. 臨牀透析 26 : 653-660, 2010.
 
6) Barisic I, et al : β2 microglobuline plasma level and painful shoulder in haemodialysed patients. Coll Antropol 34 (Suppl 1) : 315-320, 2010.
 
7) Nagoshi M, et al : Hemodialysis-related subacromial lesion : diagnostic imaging and minimally invasive treatment. Clin Nephrol 54 : 112-120, 2000.
PubMed
8) アミロイドーシス診療ガイドライン 2010 (厚生労働省科学研究費補助金難治性疾患克服研究事業アミロイドーシスに関する調査研究班編), p27-31, 2010.
 
9) 宮本達也 : 血液透析と脊椎障害 (頸椎). 関節外科 22 : 1415-1419, 2003.
 
10) 佐藤美穂子, ほか : 頸髄症を合併した透析患者の下肢理学所見-手術例の下肢筋力低下と深部腱反射-. 腎と透析 70 (別冊 : 腎不全外科 2011) : 90-93, 2011.
 
11) 田中雅人, ほか : 透析アミロイドーシスによる骨関節障害-透析と骨関節症-. Jpn J Rehabil Med 55 : 674-681, 2018.
Medical*Online
12) 田中雅人 : 透析性 (破壊性) 脊椎症. 整形外科臨床パサージュ (中村耕三総編), p131-139, 中山書店, 2012.
 
13) Chikuda H, et al : Mortality and morbidity in dialysis-dependent patients undergoing spinal surgery : analysis of a national administrative database in Japan. J Bone Joint Surg Am 94 : 433-438, 2012.
PubMed
14) 田中雅人, ほか : 血液透析に伴う脊椎障害術後成績不良例の分析. 脊椎脊髄ジャーナル 22 : 1054-1061, 2009.
 
15) 吉田綾, ほか : 長期血液透析患者の腰椎病変に対する外科的治療成績-長期観察結果-. 日本脊椎脊髄病学会雑誌 16 : 506-510, 2005.
Medical*Online
P.208 掲載の参考文献
1) 急性・慢性心不全診療ガイドライン [2017年改訂版] (日本循環器学会, ほか), 2022年4月1日更新.
 
2) 花房則男, ほか : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
3) Parfrey PS, et al : Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11 : 1277-1285, 1996.
PubMed
4) Harnett JD, et al : Congestive heart failure in dialysis patients : prevalence, incidence, prognosis and risk factors. Kidney Int 47 : 884-890, 1995.
PubMed
5) Longenecker JC, et al : Traditional cardiovascular disease risk factors in dialysis patients compared with the general population : the CHOICE Study. J Am Soc Nephrol 13 : 1918-1927, 2002.
PubMed
6) Urena P, et al : Evolutive aortic stenosis in hemodialysis patients : analysis of risk factors. Nephrologie 20 : 217-225, 1999.
PubMed
7) Myerburg RJ, et al : Interpretation of outcomes of antiarrhythmic clinical trials : design features and population impact. Circulation 97 : 1514-1521, 1998.
PubMed
8) Freeman RV, Otto CM : Spectrum of calcific aortic valve disease : pathogenesis, disease progression, and treatment strategies. Circulation 111 : 3316-3326, 2005.
PubMed
9) Banerjee D, et al : Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2 : 1186-1190, 2007.
PubMed
10) Tzamaloukas AH, et al : Serum tonicity, extracellular volume and clinical manifestations in symptomatic dialysis-associated hyperglycemia treated only with insulin. Int J Artif Organs 27 : 751-758, 2004.
PubMed
11) Herzog CA, et al : Clinical characteristics of dialysis patients with acute myocardial infarction in the United States : a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116 : 1465-1472, 2007.
 
12) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 日本透析医学会雑誌 44 : 337-425, 2011.
 
13) Jessup M, Brozena S : Heart failure. N Engl J Med 348 : 2007-2018, 2003.
PubMed
14) Tang CH, et al : Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure : A 10-Year Cohort. J Am Heart Assoc 5 : e002584, 2016.
PubMed
15) Chan KE, et al : Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 : 2223-2233, 2009.
PubMed
P.215 掲載の参考文献
1) Alfrey AC, et al : Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 18 : 257-261, 1972.
PubMed
2) Alfrey AC, et al : The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294 : 184-188, 1976.
PubMed
3) Parkinson IS, et al : Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1 (8113) : 406-409, 1979.
PubMed
4) Smith DB, et al : Dialysis encephalopathy in peritoneal dialysis. JAMA 244 : 365-366, 1980.
PubMed
5) Russo LS, et al : Aluminium intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psychiatry 55 : 697-700, 1992.
PubMed
6) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (4 Suppl 3) : S1-201, 2003.
 
7) Jaffe JA, et al : Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis 46 : 316-319, 2005.
PubMed
8) Shirley DG, Lote CJ : Renal handling of aluminium. Nephron Physiol 101 : 99-103, 2005.
 
9) Burgess E, et al : Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency. Am J Med 92 : 471-475, 1992.
PubMed
10) Stein G, et al : Desferrioxamine (DFO) in the detection and treatment of aluminum intoxication in dialysis patients. Z Klin Med 46 : 1071-1076, 1991.
 
11) Barron J, et al : A new approach to the early detection of dialysis encephalopathy. Br J Disord Commun 15 : 75-85, 1980.
 
12) Harrington CR, et al : Alzheimer's-disease-like changes in tau protein processing : association with aluminium accumulation in brains of renal dialysis patients. Lancet 343 : 993-997, 1994.
PubMed
13) Jack R, et al : Dialysis encephalopathy : a review. Int J Psychiatry Med 13 : 309-326, 1983.
PubMed
14) Lederman RJ, Henry CE : Progressive dialysis encephalopathy. Ann Neurol 4 : 199-204, 1978.
PubMed
15) Luda E : The EEG in progressive dialysis encephalopathy : the EEG in diagnosing and screening for PDE. (Part. I). Ital J Neurol Sci 5 : 369-373, 1984.
PubMed
16) Chen Y, et al : Advances in dialysis encephalopathy research : a review. Neurol Sci 39 : 1151-1159, 2018.
PubMed
17) Seifter JL, Samuels MA : Uremic encephalopathy and other brain disorders associated with renal failure. Semin Neurol 31 : 139-143, 2011.
PubMed
18) Kumar G, Goyal MK : Lentiform Fork sign : a unique MRI picture. Is metabolic acidosis responsible? Clin Neurol Neurosurg 112 : 805-812, 2010.
PubMed
19) Mossuto L, et al : Central pontine myelinolysis : diagnosis by computed tomography, magnetic resonance and evoked potentials. Ital J Neurol Sci 7 : 591-596, 1986.
PubMed
20) Menger H, Jorg J : Outcome of central pontine and extrapontine myelinolysis (n = 44). J Neurol 246 : 700-705, 1999.
PubMed
21) Epperla N, et al : Osmotic demyelination syndrome. WMJ 113 : 197-198, 2014.
PubMed
22) Shigekiyo T, et al : Antecedent diffuse cerebellar lesions on diffusion-weighted MRI in nonalcoholic Wernicke's encephalopathy. Neurol Sci 39 : 789-790, 2018.
PubMed
23) Antunez E, et al : Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. AJR Am J Roentgenol 171 : 1131-1137, 1998.
 
24) Van Cutsem J, Boelaert JR : Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36 : 1061-1068, 1989.
PubMed
25) Boelaert JR, et al : Deferoxamine therapy and mucormycosis in dialysis patients : report of an international registry. Am J Kidney Dis 18 : 660-667, 1991.
PubMed
P.220 掲載の参考文献
1) 大平整爾 (編) : 維持血液透析のVA : その現況と課題-基礎疾患および患者背景の変貌への備え. バスキュラーアクセスを極める, p13-18, 日本メディカルセンター, 2015.
 
2) 日本透析医学会 : バスキュラーアクセストラブルの管理. 2011年版 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 日本透析医学会雑誌 44 : 906-931, 2011.
 
3) 池田潔 : PTA ? 外科的再建か? 選択の分水嶺を見極める. 腎と透析 72 (別冊アクセス 2012) : 16-18, 2012.
 
4) 天野泉 : バスキュラーアクセスとIVR. 臨床画像 12 : 1186-1194, 2005.
 
5) 久木田和丘, 服部優宏 : (6) バスキュラーアクセス (AVF, AVG) の閉塞に対する外科治療. バスキュラーアクセス治療学 (大平整爾監), p204-207, 中外医学社, 2013.
 
6) 久木田和丘, ほか : Vascular accessの修復術. (7) 瘤形成. バスキュラーアクセス実践ガイド (大平整爾編), p120-123, 診断と治療社, 2007.
 
7) 濱之上哲, 宮田昭 : 高齢者の全身状態とシャント. 臨牀透析 32 : 831-852, 2016.
 
8) 春口洋昭 : スチール症候群. バスキュラーアクセスその作製・維持・修復の実際 (大平整爾編), p142-147, 中外医学社, 2007.
 
9) 安部望, ほか : 過剰血流. バスキュラーアクセスのトラブルシューティング (春口洋昭編), p54-60, 日本医事新報社, 2022.
 
10) 副島一晃 : バスキュラーアクセス合併症と修復法感染. バスキュラーアクセスその作製・維持・修復の実際 (大平整爾編), p160-167, 中外医学社, 2007.
 
11) 室谷典義 : VAトラブルの管理・対策瘤/血清腫. 臨牀透析 38 : 938-944, 2022.
 
12) 久木田和丘, 後藤順一 : 血管痛. バスキュラーアクセスのトラブルシューティング (春口洋昭編), p156-161, 日本医事新報社, 2022.
 
P.225 掲載の参考文献
1) 脳卒中治療ガイドライン 2021 (日本脳卒中学会脳卒中ガイドライン委員会編), 協和企画, 2021.
 
2) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 日本透析医学会雑誌 44 : 337-425, 2011.
 
3) 花房則男, ほか : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
4) Iseki K, et al : Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 44 : 1086-1090, 1993.
PubMed
5) 三瀬直文, ほか : メシル酸ナファモスタットによる重篤な薬剤アレルギーの検討. 日本透析医学会雑誌 37 : 65-70, 2004.
 
6) Zheng D, et al : Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. Am J Kidney Dis 68 : 94-102, 2016.
PubMed
7) Burgess LG, et al : Evaluation of Acute Kidney Injury and Mortality After Intensive Blood Pressure Control in Patients With Intracerebral Hemorrhage. J Am Heart Assoc 7 : e008439, 2018.
PubMed
8) Anderson CS, et al : Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT) : a randomised pilot trial. Lancet Neurol 7 : 391-399, 2008.
PubMed
9) Onoyama K, et al : Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J 27 : 685-691, 1986.
PubMed
10) Osaki Y, et al : Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Hypertens Res 21 : 169-173, 1998.
PubMed
11) The International Stroke Trial (IST) : a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349 : 1569-1581, 1997.
 
12) 静注血栓溶解 (rt-PA) 療法適正治療指針 第三版 2019年3月 (日本脳卒中学会脳卒中医療向上・社会保険委員会/静注血栓溶解療法指針改訂部会編).
 
13) 豊田一則 : 維持血液透析患者における脳梗塞急性期のエダラボン治療. Geriatric Medicine 41 : 673-679, 2003.
Medical*Online
14) Chan KE, et al : Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 : 2223-2233, 2009.
PubMed
P.230 掲載の参考文献
1) Pisoni RL, et al : Pruritus in haemodialysis patients : International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21 : 3495-3505, 2006.
PubMed
2) Sukul N, et al : Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med 3 : 42-53.e1, 2021.
 
3) 川島眞, ほか : 透析患者にみられる皮膚症状-特にドライスキンについて-. 腎と透析 75 : 275-281, 2013.
Medical*Online
4) 高森健二, ほか : 透析の痒み : その病態. Visual Dermatology 11 : 708-713, 2012.
 
5) Kumagai H, et al : Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In : Itch : Basic Mechanisms and Therapy (ed by Yosipovitch G, et al), p279-286, New York, Marcel Dekker, 2004.
 
6) Wieczorek A, et al : Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. J Eur Acad Dermatol Venereol 34 : 2368-2372, 2020.
PubMed
7) 江畑俊哉, ほか : 5D itch scale 日本語版の作成. 日本皮膚科学会雑誌 125 : 1035-1040, 2015.
 
8) 高橋直子 : II 病態に関する対応 2 かゆみの対応. 一歩先の透析医療理論と実践 (山川智之編), p137-154, 中外医学社, 2020.
 
9) Takahashi N, et al : Response of patients with hemodialysis-associated pruritus to new treatment algorithm with nalfurafine hydrochloride : a retrospective survey-based study. Ren Replace Ther 2 : 27, 2016.
 
10) Takahashi N, et al : Effectiveness of a treatment algorithm for hemodialysis-associated pruritus in terms of changes in medications. Ren Replace Ther 7 : 24, 2021.
 
11) 高橋直子 : PMMA膜 : NF膜による掻痒と栄養状態改善への期待. 腎と透析 83 (別冊ハイパフォーマンスメンブレン '17) : 118-121, 2017.
 
12) 長沼俊秀, ほか : 血液浄化器-除去分画特性の軌跡. 人工臓器 49 : 45-48, 2020.
 
13) Shirazian S, et al : Chronic kidney disease-associated pruritus : impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis 10 : 11-26, 2017.
PubMed
14) Kumagai H, et al : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2010.
PubMed
15) 山口敬介 : この薬は "いつ" "どの患者で" "どう使う"? (5) GABAアナログ. 薬局 69 : 2446-2452, 2018.
 
P.233 掲載の参考文献
1) Agarwal R : Dialysis disequilibrium syndrome. UpToDate. 2022.
 
2) Raina R, et al : Dialysis disequilibrium syndrome (DDS) in pediatric patients on dialysis : systematic review and clinical practice recommendations. Pediatr Nephrol 37 : 263-274, 2022.
PubMed
3) Silver SM, et al : Dialysis disequilibrium syndrome (DDS) in the rat : role of the "reverse urea effect". Kidney Int 42 : 161-166, 1992.
PubMed
4) Silver SM : Cerebral edema after rapid dialysis is not caused by an increase in brain organic osmolytes. J Am Soc Nephrol 6 : 1600-1606, 1995.
 
5) Trinh-Trang-Tan MM, et al : Molecular basis for the dialysis disequilibrium syndrome : altered aquaporin and urea transporter expression in the brain. Nephrol Dial Transplant 20 : 1984-1988, 2005.
PubMed
6) Mistry K : Dialysis disequilibrium syndrome prevention and management. Int J Nephrol Renovasc Dis 12 : 69-77, 2019.
PubMed
7) Galons JP, et al : Hemodialysis increases apparent diffusion coefficient of brain water in nephrectomized rats measured by isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest 98 : 750-755, 1996.
PubMed
8) Chen CL, et al : A preliminary report of brain edema in patients with uremia at first hemodialysis : evaluation by diffusion-weighted MR imaging. AJNR Am J Neuroradiol 28 : 68-71, 2007.
 
9) Arieff AI : Dialysis disequilibrium syndrome : current concepts on pathogenesis and prevention. Kidney Int 45 : 629-635, 1994.
PubMed
10) Patel N, et al : Dialysis disequilibrium syndrome : A narrative review. Semin Dial 21 : 493-498, 2008.
PubMed
11) Arieff AI, et al : Brain water and electrolyte metabolism in uremia : effects of slow and rapid hemodialysis. Kidney Int 4 : 177-187, 1973.
PubMed
12) Zepeda-Orozco D, Quigley R : Dialysis disequilibrium syndrome. Pediatr Nephrol 27 : 2205-2211, 2012.
PubMed
13) Florea B, et al : EEG spectral changes induced by hemodialysis. Clin Neurophysiol Pract 6 : 146-148, 2021.
PubMed
14) 脳卒中治療ガイドライン 2009, 脳梗塞急性期 1-6 脳浮腫管理, 高血圧性脳出血の非手術的治療 2-3 脳浮腫・頭蓋内圧亢進の管理. (日本脳卒中学会脳卒中ガイドライン委員会編), p60, p142-143, 協和企画, 2009.
 
P.239 掲載の参考文献
1) 田部井薫 : 不整脈 ; 維持透析患者にみられる病態. 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 [第2版] 下, p267-272, 日本臨牀社, 2012.
 
2) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 日本透析医学会雑誌 44 : 337-425, 2011.
 
3) Pun PH : The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis 21 : 480-488, 2014.
PubMed
4) Herzog CA, et al : Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 68 : 818-825, 2005.
PubMed
5) Bleyer AJ, et al : Characteristics of sudden death in hemodialysis patients. Kidney Int 69 : 2268-2273, 2006.
PubMed
6) Kimura K, et al : Cardiac arrhythmias in hemodialysis patients. A study of incidence and contributory factors. Nephron 53 : 201-207, 1989.
PubMed
7) Zimmerman D, et al : Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27 : 3816-3822, 2012.
PubMed
8) Wizemann V, et al : Atrial fibrillation in hemodialysis patients : clinical features and associations with anticoagulant therapy. Kidney Int 77 : 1098-1106, 2010.
PubMed
9) Joki N, et al : Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 12 : 718-723, 1997.
PubMed
10) 伊藤聖学, ほか : 透析患者の危険な心電図異常疫学, 病態, 診断も含めて. 臨牀透析 31 : 373-380, 2015.
 
11) Kimura K, et al : Ventricular tachyarrhythmia treated by parathyroidectomy in a chronically hemodialyzed patient. Nephron 53 : 176-177, 1989.
 
12) 池田隆徳 : 不整脈の分類とメカニズム ; 不整脈. 別冊日本臨牀領域別症候群シリーズ No.7 循環器症候群 [第3版] III, p7-11, 日本臨牀社, 2019.
 
13) Cice G, et al : Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy : a prospective, placebo-controlled trial. J Am Coll Cardiol 41 : 1438-1444, 2003.
 
14) Chung I, et al : Catheter ablation for atrial fibrillation in patients with chronic kidney disease and on dialysis-a meta-analysis and review. Cardiorenal Med, 2022. (DOI : 10.1159/000525388)
 
15) El-Chami MF, et al : Long-term survival of implantable cardioverter defibrillator recipients with end-stage renal disease. J Arrhythm 33 : 459-462, 2017.
PubMed
16) Lehrich RW, et al : Automated external defibrillators and survival from cardiac arrest in the outpatient hemodialysis clinic. J Am Soc Nephrol 18 : 312-320, 2007.
PubMed
17) Pun PH, et al : Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 79 : 218-227, 2011.
PubMed
18) Uchida T, et al : Lethal ventricular arrhythmia can be prevented by adjusting the dialysate potassium concentration and the use of anti-arrhythmic agents : a case report and literature review. Ren Replace Ther 8 : 20, 2022.
 
19) Ookawara S, et al : Hemodialysis crossover study using a relative blood volume change-guided ultrafiltration control compared with standard hemodialysis : the BV-UFC study. Ren Replace Ther 6 : 45, 2020.
 
P.245 掲載の参考文献
1) Qunibi WY : Adynamic bone disease associated with chronic kidney. UpToDate. (last updated Sep 23, 2021)
 
2) Moe S, et al : Kidney Disease : Improving Global Outcomes (KDIGO) : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006.
PubMed
3) Chapter 1 : Introduction and definition of CKD-MBD and the development of the guideline statements. Kidney Int 76113 : S3-8, 2009.
PubMed
4) Drueke TB, Massy ZA : Changing bone patterns with progression of chronic kidney disease. Kidney Int 89 : 289-302, 2016.
PubMed
5) Jamal SA, et al : Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease : an updated systematic review and metaanalysis. Lancet 382 : 1268-1277, 2013.
PubMed
6) Evenepoel P, et al : Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis. J Clin Endocrinol Metab 6 : dgac522, 2022.
 
7) Haarhaus M, et al : Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100 : 546-558, 2021.
PubMed
8) Ferreira A, et al : Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19 : 405-412, 2008.
 
9) Haris A, et al : Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 70 : 931-937, 2006.
PubMed
10) Goodman WG, et al : Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46 : 1160-1166, 1994.
PubMed
11) van de Peppel J, van Leeuwen JP : Vitamin D and gene networks in human osteoblasts. Front Physiol 5 : 137, 2014.
PubMed
12) Behets GJ, et al : Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87 : 846-856, 2015.
PubMed
13) Malluche HH, et al : An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69 : 269-278, 2008.
 
14) Spoendlin J, et al : Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med 179 : 741-749, 2019.
PubMed
15) Malluche HH, et al : Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 23 : 525-532, 2012.
PubMed
16) Ginsberg C, Ix JH : Diagnosis and Management of Osteoporosis in Advanced Kidney Disease : A Review. Am J Kidney Dis 79 : 427-436, 2022.
PubMed
17) J-DAVID Investigators ; Shoji T, et al : Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis : The J-DAVID Randomized Clinical Trial. JAMA 320 : 2325-2334, 2018.
 
18) Peugh J, et al : Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease. JBMR Plus 3 : e10176, 2019.
PubMed
P.250 掲載の参考文献
1) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日本透析医学会雑誌 45 : 301-356, 2012.
 
2) Taniguchi M, et al : Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17 : 221-228, 2013.
PubMed
3) 日本透析医学会 : WADDA system Ver2.1. [https://member.jsdt.or.jp/member/statistics]
 
4) Centeno PP, et al : Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10 : 4693, 2019.
PubMed
5) Komaba H, Fukagawa M : FGF23-parathyroid interaction : implications in chronic kidney disease. Kidney Int 77 : 292-298, 2010.
PubMed
6) Komaba H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010.
PubMed
7) Jadoul M, et al : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70 : 1358-1366, 2006.
PubMed
8) Kir S, et al : PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer. Cell Metab 23 : 315-323, 2016.
PubMed
9) Komaba H, et al : Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients : results from the DOPPS. J Cachexia Sarcopenia Muscle 12 : 855-865, 2021.
PubMed
10) Gutierrez OM, et al : Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 : 584-592, 2008.
PubMed
11) Faul C, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011.
PubMed
12) Komaba H, et al : Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement : five case studies and a literature review. NDT Plus 1 : iii54-iii58, 2008.
 
13) J-DAVID Investigators ; Shoji T, et al : Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis : The J-DAVID Randomized Clinical Trial. JAMA 320 : 2325-2334, 2018.
 
14) EVOLVE Trial Investigators ; Chertow GM, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012.
PubMed
15) Komaba H, et al : Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab 107 : 2016-2025, 2022.
PubMed
P.257 掲載の参考文献
1) 総務省統計局 : 統計からみた我が国の高齢者. 統計トピックス 121, 2019. [https://www.stat.go.jp/data/topics/pdf/topics121.pdf]
 
2) 日本透析医学会統計調査委員会 ; 花房規男, ほか : わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析医学会雑誌 54 : 611-657, 2021.
 
3) Fouque D, et al : A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 : 391-398, 2008.
PubMed
4) Kobayashi I, et al : Geriatric Nutritional Risk Index, a simplified nutritional screening index, is a significant predictor of mortality in chronic dialysis patients. Nephrol Dial Transplant 25 : 3361-3365, 2010.
PubMed
5) Kalantar-Zadeh K, et al : Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80 : 299-307, 2004.
PubMed
6) Kang SS, et al : Nutritional Status Predicts 10-Year Mortality in Patients with End-Stage Renal Disease on Hemodialysis. Nutrients 9 : 399, 2017.
PubMed
7) 日本透析医学会 : 図説わが国の慢性透析療法の現況 2015年12月31日現在, 2016.
 
8) Chen LK, et al : Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 : 95-101, 2014.
 
9) Chen LK, et al : Asian Working Group for Sarcopenia : 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc 21 : 300-307.e2, 2020.
 
10) サルコペニア診療ガイドライン 2017年版 一部改訂 (サルコペニア診療ガイドライン作成委員会編), 日本サルコペニア・フレイル学会, 国立長寿医療研究センター, 2020.
 
11) Shu X, et al : Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients : a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 13 : 145-158, 2022.
PubMed
12) Fried LP, et al : Frailty in older adults : evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 : M146-156, 2001.
PubMed
13) Satake S, et al : The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria). Geriatr Gerontol Int 20 : 992-993, 2020.
PubMed
14) Yamada M, Arai H : Predictive Value of Frailty Scores for Healthy Life Expectancy in Community-Dwelling Older Japanese Adults. J Am Med Dir Assoc 16 : 1002.e7-11, 2015.
 
15) Lee HJ, Son YJ : Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis : A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 18 : 3471, 2021.
PubMed
16) Mehrotra R, Kopple JD : Nutritional management of maintenance dialysis patients : why aren't we doing better? Annu Rev Nutr 21 : 343-379, 2001.
PubMed
17) 日本透析医学会学術委員会ガイドライン作成小委員会栄養問題検討ワーキンググループ : 慢性透析患者の食事療法基準. 日本透析医学会雑誌 47 : 287-291, 2014.
 
18) Kim JC, et al : Frailty and protein-energy wasting in elderly patients with end stage kidney disease. J Am Soc Nephrol 24 : 337-351, 2013.
PubMed
19) Kanda E, et al : The combination of malnutrition-inflammation and functional status limitations is associated with mortality in hemodialysis patients. Sci Rep 11 : 1582, 2021.
PubMed
20) Ohkawa S, et al : Optimum dietary protein requirement in nondiabetic maintenance hemodialysis patients. Am J Kidney Dis 43 : 454-463, 2004.
PubMed
21) Ravel VA, et al : Low protein nitrogen appearance as a surrogate of low dietary protein intake is associated with higher all-cause mortality in maintenance hemodialysis patients. J Nutr 143 : 1084-1092, 2013.
PubMed
22) Kanda E, et al : A new nutritional risk index for predicting mortality in hemodialysis patients : Nationwide cohort study. PLoS One 14 : e0214524, 2019.
PubMed
23) Matsuzawa R, et al : The effects of amino acid/protein supplementation in patients undergoing hemodialysis : A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN 44 : 114-121, 2021.
PubMed
24) Sheng K, et al : Intradialytic exercise in hemodialysis patients : a systematic review and meta-analysis. Am J Nephrol 40 : 478-490, 2014.
PubMed
25) Bernier-Jean A, et al : Exercise training for adults undergoing maintenance dialysis. Cochrane Database Syst Rev 1 : CD014653, 2022.
PubMed
26) 腎臓リハビリテーションガイドライン (日本腎臓リハビリテーション学会編), 南江堂, 2018.
 
27) Pisoni RL, et al : DOPPS practice monitor to help evaluate impact of bundle on hemodialysis patient care. Nephrol News Issues 24 : 28, 30, 2010.
PubMed

XIII 中毒性腎障害 ( 薬物性腎障害, 化学物質による腎障害 )

P.264 掲載の参考文献
1) van der Woude FJ : Cocaine use and kidney damage. Nephrol Dial Transplant 15 : 299-301, 2000.
PubMed
2) Wan SH, Szeto ML : Rabdomyolysis and heroin addiction. HKMJ 1 : 266-268, 1995.
 
3) Campbell GA, et al : The agony of ecstasy : MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol 3 : 1852-1860, 2008.
PubMed
4) 令和3年版 警察白書. [https://www.npa.go.jp/hakusyo/r03/index.html]
 
5) Ishigami A, et al : Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers. Leg Med (Tokyo) 5 : 42-48, 2003.
PubMed
6) Tokunaga I, et al : Changes in renal function and oxidative damage in methamphetamine-treated rat. Leg Med (Tokyo) 8 : 16-21, 2006.
PubMed
7) Matsusue A, et al : Genetic analysis of the rhabdomyolysis-associated genes in forensic autopsy cases of methamphetamine abusers. Leg Med (Tokyo) 13 : 7-11, 2011.
PubMed
P.268 掲載の参考文献
1) Teng L, et al : Herbal medicines : challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol 9 : 1225-1233, 2016.
PubMed
2) Wang Y, et al : Hospital-acquired and community-acquired acute renal failure in hospitalized Chinese : a ten-year review. Ren Fail 29 : 163-168, 2007.
 
3) Kilis-Pstrusinska K, Wiela-Hojenska A : Nephrotoxicity of herbal products in Europe-A review of an underestimated problem. Int J Mol Sci 22 : 4132, 2021.
PubMed
4) Debelle FD, et al : Aristolochic acid nephropathy : a worldwide problem. Kidney Int 74 : 158-169, 2008.
PubMed
5) 合田幸広 : 漢方薬・生薬の品質保証. 臨床検査 53 : 873-877, 2009.
 
6) Katsoulieris E, et al : Lipotoxicity in renal proximal tubular cells : relationship between endoplasmic reticulum stress and oxidative stress pathways. Free Radic Biol Med 48 : 1654-1662, 2010.
PubMed
7) Decleves AE, et al : Protective effect of nitric oxide in aristolochic acid-induced toxic acute kidney injury : an old friend with new assets. Exp Physiol 101 : 193-206, 2016.
PubMed
8) Pozdzik AA, et al : Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. Nephrol Dial Transplant 23 : 2480-2491, 2008.
PubMed
9) Yang L, et al : Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 22 : 445-456, 2007.
PubMed
10) Zhang WX, et al : Andrographolide induced acute kidney injury : Analysis of 26 cases reported in Chinese Literature. Nephrology (Carlton) 19 : 21-26, 2014.
 
11) Yang B, et al : Nephrotoxicity and Chinese Herbal Medicine. Clin J Am Soc Nephrol 13 : 1605-1611, 2018.
PubMed
12) 吉野鉄大 : 偽性アルドステロン症甘草に注意. Medicina 58 : 1252-1257, 2021.
 
P.273 掲載の参考文献
1) Yu ASL, et al (ed) : Brenner and Rector's The Kidney, 11th ed, Elsevier, Amsterdam, 2020.
 
2) ONTARGET Investigators, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008.
 
3) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
4) Bakris GL, et al : Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383 : 2219-2229, 2020.
PubMed
5) Ando K, et al : Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria : a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2 : 944-953, 2014.
PubMed
6) Wanner C, et al : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 : 323-334, 2016.
PubMed
7) Perkovic V, et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380 : 2295-2306, 2019.
PubMed
8) Heerspink HJL, et al : Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383 : 1436-1446, 2020.
PubMed
9) Zhao M, et al : Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clin J Am Soc Nephrol 16 : 70-78, 2020.
PubMed
10) 要伸也 : 降圧薬による腎障害. 別冊日本臨牀新領域別症候群シリーズ No.17 腎臓症候群 [第2版] 上, p690-694, 日本臨牀社, 2012.
 
P.278 掲載の参考文献
1) 薬剤性腎障害の診療ガイドライン作成委員会 : 薬剤性腎障害診療ガイドライン 2016. 日本腎臓学会誌 58 : 477-555, 2016.
 
2) Izzedine H, et al : Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 : 804-817, 2005.
PubMed
3) Perazella MA, et al : Drug-Induced Acute Kidney Injury. Clin J Am Soc Nephrol 17 : 1220-1233, 2022.
PubMed
4) Ormrod D, et al : Valaciclovir : a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 59 : 839-863, 2000.
PubMed
5) Roberts DM, et al : Acute kidney injury due to crystalluria following acute valacyclovir overdose. Kidney Int 79 : 574, 2011.
PubMed
6) Griffiths P, et al : The pathogenesis of human cytomegalovirus. J Pathol 235 : 288-297, 2015.
PubMed
7) Deffert C, et al : Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury. Kidney Int Rep 5 : 2102-2108, 2020.
PubMed
8) Hong YS, et al : Hepatitis B virus infection and development of chronic kidney disease : a cohort study. BMC Nephrol 19 : 353, 2018.
 
9) Lee JJ, et al : Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 9 : e100790, 2014.
PubMed
10) 日本透析医学会 : わが国の慢性透析療法の現況 (2018年12月31日現在). 日本透析医学会雑誌 52 : 679-754, 2019. [https://docs.jsdt.or.jp/overview/file/2018/pdf/2018all.pdf]
 
11) B型肝炎治療ガイドライン (第4版) (日本肝臓学会肝炎診療ガイドライン作成委員会編), 2022年6月. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v4.pdf]
 
12) Fung J, et al : Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol 29 : 428-434, 2014.
PubMed
13) C型肝炎治療ガイドライン (第8.1版) (日本肝臓学会肝炎診療ガイドライン作成委員会編), 2022年5月. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/C_v8.1.pdf]
 
14) Geetha D, et al : Impact of the COVID-19 pandemic on the kidney community : lessons learned and future directions. Nat Rev Nephrol, 2022. (DOI : 10.1038/s41581-022-00618-4)
 
15) 厚生労働省 : 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第8.0版, 2022年7月22日. [https://www.mhlw.go.jp/content/000936655.pdf]
 
16) 日本感染症学会 : COVID-19に対する薬物治療の考え方 第13.1版, 2022年2月18日. [https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_220218.pdf]
 
17) Adamsick ML, et al : Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J Am Soc Nephrol 31 : 1384-1386, 2020.
PubMed
18) Ackley TW, et al : A Valid Warning or Clinical Lore : an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrob Agents Chemother 65 : e02290-20, 2021.
 
19) Thakare S, et al : Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep 6 : 206-210, 2021.
PubMed
20) Aiswarya D, et al : Use of Remdesivir in Patients With COVID-19 on Hemodialysis : A Study of Safety and Tolerance. Kidney Int Rep 6 : 586-593, 2021.
PubMed
21) Kikuchi K, et al : Survival and predictive factors in dialysis patients with COVID-19 in Japan : a nationwide cohort study. Ren Replace Ther 7 : 59, 2021.
PubMed
22) Villamarin M, et al : Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients. Transplantation, 2022. (DOI : 10.1097/TP.0000000000004306)
 
23) Takashita E, et al : Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med 387 : 468-470, 2022.
PubMed
P.283 掲載の参考文献
1) 薬剤性腎障害の診療ガイドライン作成委員会 : 薬剤性腎障害診療ガイドライン 2016. 日本腎臓学会誌 58 : 477-555, 2016.
 
2) 横山仁 : 疫学調査 (日本腎臓学会レジストリー) 報告厚生労働省科学研究費補助金「慢性腎臓病の進行を促進する薬剤等による腎障害の早期診断法と治療法の開発」平成25年度 総括・分担研究報告書, 2014.
 
3) Usui J, et al : Clinical practice guideline for drug-induced kidney injury in Japan 2016 : digest version. Clin Exp Nephrol 20 : 827-831, 2016.
PubMed
4) Bamgbola O : Review of vancomycin-induced renal toxicity : an update. Ther Adv Endocrinol Metab 7 : 136-147, 2016.
PubMed
5) 成田一衛 : 抗菌薬による腎障害. 日本腎臓学会誌 58 : 1069-1072, 2016.
 
6) Muriithi AK, et al : Biopsy-proven acute interstitial nephritis, 1993-2011 : a case series. Am J Kidney Dis 64 : 558-566, 2014.
PubMed
7) 湯澤由紀夫, 伊藤功 : 尿中NAG, 尿中β2ミクログロブリン-尿細管障害・AKIとバイオマーカー. 日本内科学会雑誌 97 : 971-978, 2008.
 
8) Perazella MA : Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease. Adv Chronic Kidney Dis 24 : 57-63, 2017.
PubMed
9) Moledina DG, Perazella MA : Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol 12 : 2046-2049, 2017.
PubMed
10) Gonzalez E, et al : Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73 : 940-946, 2008.
PubMed
11) Muriithi AK, et al : Biopsy-proven acute interstitial nephritis, 1993-2011 : a case series. Am J Kidney Dis 64 : 558-566, 2014.
PubMed
12) Muriithi AK, et al : Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 87 : 458-464, 2015.
PubMed
13) Trof RJ, et al : Biomarkers of acute renal injury and renal failure. Shock 26 : 245-253, 2006.
PubMed
P.289 掲載の参考文献
1) Delay J, Deniker P : Drug-induced extrapyramidal syndrome. In : Handbook of Clinical Neurology (ed by Vinken P, Bruyn G), p248-266, North-Holland Publishing Company. Amsterdam 1968.
 
2) Caroff SN, Mann SC : Neuroleptic malignant syndrome. Med Clin North Am 77 : 185-202, 1993.
PubMed
3) Stubner S, et al : Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37 (Supple 1) : S54-64, 2004.
 
4) Levenson JL : Neuroleptic malignant syndrome. Am J Psychiatry 142 : 1137-1145, 1985.
PubMed
5) Keck PE, et al : Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 46 : 914-918, 1989.
PubMed
6) 西嶋康一 : 第二世代抗精神病薬の時代における悪性症候群. 臨床精神薬理 22 : 385-393, 2019.
 
7) Friedman LS, et al : Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 147 : 1495-1497, 1987.
PubMed
8) Buckley PF, Hutchinson M : Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 58 : 271-273, 1995.
PubMed
9) Gburek J, et al : Renal uptake of myoglobin is mediated by the endocytic receptors megalin and cubilin. Am J Physiol Renal Physiol 285 : F451-458, 2003.
PubMed
10) Pope HG, et al : Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143 : 1227-1233, 1986.
 
11) 竹田徹朗 : 向精神薬による副作用としての腎機能障害. 臨床精神薬理 22 : 893-898, 2019.
 
12) Endo M, et al : Changes in the Ca induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomedical Res 4 : 83-92, 1983.
 
13) 川本進也 : 第12章 薬物療法 E. 副作用 臨床てんかん学. p86-488, 医学書院, 2016.
 
P.293 掲載の参考文献
1) Cvitkovic E, et al : Improvement of cis-dichlorodiammineplatinum (NSC 119875) : therapeutic index in an animal model. Cancer 39 : 1357-1361, 1977.
 
2) Sasaki Y, et al : Pharmacokinetics of (glycolate-0,0') -diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23 : 243-246, 1989.
 
3) Hotta K, et al : Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy : results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43 : 1115-1123, 2013.
 
4) Horinouchi H, et al : Short hydration in chemotherapy containing cisplatin (≧75 mg/m2) for patients with lung cancer : a prospective study. Jpn J Clin Oncol 43 : 1105-1109, 2013.
 
5) Yokoo K, et al : Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13 : 578-584, 2009.
PubMed
6) Widemann BC, Adamson PC : Understanding and managing methotrexate nephrotoxicity. Oncologist 11 : 694-703, 2006.
PubMed
7) Perazella MA : Onco-nephrology : renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7 : 1713-1721, 2012.
PubMed
8) Ensergueix G, et al : Ifosfamide nephrotoxicity in adult patients. Clin Kidney J 13 : 660-665, 2020.
PubMed
9) Leal F, et al : Gemcitabine-related thrombotic microangiopathy : a single-centre retrospective series. J Chemother 26 : 169-172, 2014.
 
P.297 掲載の参考文献
1) Romagnoli P, et al : Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest 89 : 254-258, 1992.
 
2) Gunnarsson I, et al : HLA-DRB1*0301 and DQA1*0501 in RA. Ann Rheum Dis 60 : 727, 2001.
PubMed
3) Katz WA, et al : Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 101 : 176-179, 1984.
PubMed
4) Hoshino J, et al : Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract 104 : c15-19, 2006.
PubMed
5) Obayashi M, et al : Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol 7 : 275-278, 2003.
PubMed
6) Yoshida A, et al : Membranous glomerulonephritis in patients with rheumatoid arthritis. Clin Ther 16 : 1000-1006, 1994.
PubMed
7) Nagahama K, et al : Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 39 : 706-712, 2002.
PubMed
8) Manabe S, et al : Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis : case report and literature review. Case Rep Nephrol Dial 5 : 30-38, 2014.
 
9) Ammar A, et al : Etanercept-associated Nephropathy. Cureus 11 : e5419, 2019.
PubMed
10) Stokes MB, et al : Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20 : 1400-1406, 2005.
PubMed
11) 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版 (日本リウマチ学会MTX診療ガイドライン策定小委員会編), p20-23, 羊土社, 2016.
 
12) ゼルヤンツ 5 mg 錠 添付文書 2021年10月改訂 (第4版).
 
13) オルミエント 2 mg 錠, 4 mg 錠 添付文書 2022年6月改訂 (第6版).
 
14) ジセレカ 100 mg 錠, 200 mg 錠 添付文書 2022年3月改訂 (第4版).
 
15) スマイラフ 50 mg 錠, 100 mg 錠 添付文書 2021年10月改訂 (第2版).
 
16) リンヴォック 7.5 mg 錠, 15 mg 錠, 30 mg 錠, 45 mg 錠 添付文書 2022年9月改訂 (第9版).
 
P.301 掲載の参考文献
1) 厚生労働省 : 食中毒. 4 食中毒統計資料. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/syokuchu/04.html]
 
2) 吉川賢二 : サルモネラ感染症. 腎と透析 49 : 543-545, 2000.
 
3) 田中義之, ほか : Salmpnella typhimurium感染症により敗血症, 急性腎不全を併発した1例. 腎と透析 58 : 917-920, 2005.
 
4) 西原悠二, 細川直登 : 細菌性胃腸炎 (細菌性食中毒) 腸炎ビブリオ感染症・サルモネラ感染症. 医学と薬学 74 : 791-798, 2017.
Medical*Online
5) 浅尾努 : 食中毒. 綜合臨牀 59 : 426-430, 2010.
Medical*Online
6) Faulder KE, et al : The Epidemiology of Childhood Salmonella Infections in Alberta, Canada. Foodborne Pathog Dis 14 : 364-369, 2017.
PubMed
7) 伊良部仁, ほか : 入院治療を要した小児細菌性腸炎の臨床的検討. 小児科臨床 72 : 265-270, 2019.
Medical*Online
8) 板橋美津世, 内田啓子 : その他の感染症. 腎と透析 (2003 増刊号) : 180-182, 2003.
 
9) 大西健児, ほか : JAID/JSC感染症治療ガイドライン 2015-腸管感染症-. 感染症学雑誌 90 : 31-65, 2016.
 
10) 厚生労働省 : 感染症法に基づく医師及び獣医師の届出について. 3 腸管出血性大腸菌感染症. [https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-03-03.html]
 
11) Kamioka I, et al : Risk factors for developing severe clinical course in HUS patients : a national survey in Japan. Pediatr Int 50 : 441-446, 2008.
PubMed
12) Hickey CA, et al : Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 165 : 884-889, 2011.
PubMed
13) Melton-Celsa AR : Shiga Toxin (Stx) Classification, Structure, and Function. Microbiol Spectr 2 : EHEC-0024-2013, 2014.
 
14) 三井亜希子, 清水章 : TMA (HUS/TTPを含む) の病理組織. 日腎会誌 56 : 1031-1042, 2014.
 
15) Smith KE, et al : Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 31 : 37-41, 2012.
PubMed
16) Wong CS, et al : Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157 : H7 : a multivariable analysis. Clin Infect Dis 55 : 33-41, 2012.
PubMed
17) Guerrant RL, et al : Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32 : 331-351, 2001.
PubMed
18) Shiomi M, et al : Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157 : H7. Pediatr Int 41 : 228-232, 1999.
PubMed
19) Ikeda K, et al : Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157 : H7 infection. Clin Nephrol 52 : 357-362, 1999.
PubMed
20) 溶血性尿毒症症候群の診断・治療ガイドライン (五十嵐隆, ほか編), 東京医学社, 2014.
 
21) Orth D, et al : Shiga toxin activates complement and binds factor H : evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182 : 6394-6400, 2009.
PubMed
22) Giordano P, et al : A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatr Nephrol 34 : 517-527, 2019.
 
23) Lapeyraque AL, et al : Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364 : 2561-2563, 2011.
 
24) Menne J, et al : Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 : H4 induced haemolytic uraemic syndrome : case-control study. BMJ 345 : e4565, 2012.
 
25) Spinale JM, et al : Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28 : 2097-2105, 2013.
PubMed
26) Garg AX, et al : Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome : a systematic review, meta-analysis, and meta-regression. JAMA 290 : 1360-1370, 2003.
PubMed
27) Clark WF, et al : Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157 : H7 : a prospective cohort study. BMJ 341 : c6020, 2010.
PubMed
P.306 掲載の参考文献
1) KDIGO acute kidney injury work group : KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2 : 1-138, 2012.
 
2) AKI (急性腎障害) 診療ガイドライン 2016 (AKI (急性腎障害) 診療ガイドライン作成委員会編). 日本腎臓学会誌 59 : 419-533, 2017.
 
3) Morcos SK, et al : Contrast-media-induced nephrotoxicity : a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 9 : 1602-1613, 1999.
PubMed
4) 腎障害患者におけるヨード造影剤使用に関するガイドライン 2018 (日本腎臓学会, 日本放射線学会, 日本循環器学会編), 日本腎臓学会誌 61 : 933-1081, 2019.
 
5) McCullough PA, et al : Risk prediction of contrast-induced nephropathy. Am J Cardiol 98 : 27K-36K, 2006.
PubMed
6) Davenport MS, et al : Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material : risk stratification by using estimated glomerular filtration rate. Radiology 268 : 719-728, 2013.
PubMed
7) Murakami R, et al : Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur Radiol 22 : 2147-2152, 2012.
PubMed
8) McDonald RJ, et al : Intravenous contrast material-induced nephropathy : causal or coincident phenomenon? Radiology 267 : 106-118, 2013.
 
9) Abe M, et al : Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J 73 : 1518-1522, 2009.
PubMed
10) Rihal CS, et al : Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 : 2259-2264, 2002.
PubMed
11) Abuelo JG : Normotensive ischemic acute renal failure. N Engl J Med 357 : 797-805, 2007.
PubMed
12) Mulay SR, et al : Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29 : 507-514, 2014.
PubMed
13) Fukumoto Y, et al : The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization : a prospective study. J Am Coll Cardiol 42 : 211-216, 2003.
PubMed
14) Scolari F, Ravani P : Atheroembolic renal disease. Lancet 375 : 1650-1660, 2010.
PubMed
15) Mueller C, et al : Prevention of contrast media-associated nephropathy : randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162 : 329-336, 2002.
PubMed
16) Lee SW, et al : Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol 107 : 1447-1452, 2011.
PubMed
17) Maioli M, et al : Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 52 : 599-604, 2008.
PubMed
18) Mehran R, Nikolsky E : Contrast-induced nephropathy : definition, epidemiology, and patients at risk. Kidney Int Suppl (100) : S11-S15, 2016.
 
19) McDonald JS, et al : Acute Kidney Injury After Intravenous Versus Intra-Arterial Contrast Material Administration in a Paired Cohort. Invest Radiol 51 : 804-809, 2016.
 
20) Mehran R, et al : A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention : development and initial validation. J Am Coll Cardiol 44 : 1393-1399, 2004.
PubMed
21) Kimura T, et al : Effects of chronic kidney disease and post-angiographic acute kidney injury on long-term prognosis after coronary artery angiography. Nephrol Dial Transplant 26 : 1838-1846, 2011.
PubMed
P.311 掲載の参考文献
1) 崎尾秀彦, ほか : 当院におけるマムシ咬傷について. 臨床外科 40 : 1295-1297, 1985.
 
2) Hifumi T, et al : Venomous snake bites : clinical diagnosis and treatment. J Intensive Care 3 : 16, 2015.
PubMed
3) Casewell NR, et al : Causes and Consequences of Snake Venom Variation. Trends Pharmacol Sci 41 : 570-581, 2020.
PubMed
4) 堺淳 : 毒蛇咬症 (マムシ, ヤマカガシ) の診断と治療. 中毒研究 26 : 193-199, 2013.
 
5) 北澤康秀, 太田育夫 : 毒ヘビ咬傷概論. 近畿大学医学雑誌 42 : 79-84, 2017.
Medical*Online
6) Okubo K, et al : Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. Nat Med 24 : 232-238, 2018.
PubMed
7) Chiba T, et al : Clinical Condition and Management of 114 Mamushi (Gloydius blomhoffii) Bites in a General Hospital in Japan. Intern Med 57 : 1075-1080, 2018.
 
8) 小橋俊彦, ほか : マムシ咬傷31例の検討. 広島医学 58 : 527-531, 2005.
 
9) 瀧健治, ほか : 全国調査によるマムシ咬傷の検討. 日本臨床救急医学会雑誌 17 : 753-760, 2014.
Medical*Online
10) Yokoi H, et al : Severe hypofibrinogenemia in patients bitten by Gloydius tsushimaensis in Tsushima Island, Nagasaki, Japan, and treatment strategy. Toxicon 188 : 142-149, 2020.
PubMed
11) Yokoi H, et al : Evaluation of a Treatment Algorithm for Tsushima Mamushi (Gloydius tsushimaensis) Snakebites, after Its Introduction to Tsushima Island, Nagasaki, Japan. Intern Med 60 : 3093-3099, 2021.
PubMed
12) Park KH, et al : Effectiveness of repeated antivenom therapy for snakebite-related systemic complications. J Int Med Res 47 : 4808-4814, 2019.
PubMed
13) de Silva HA, et al : Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite : a randomised, double-blind, placebo-controlled trial. PLoS Med 8 : e1000435, 2011.
PubMed
14) Hifumi T, et al : Effect of antivenom therapy of Rhabdophis tigrinus (Yamakagashi snake) bites. J Intensive Care 2 : 44, 2014.
PubMed
P.315 掲載の参考文献
1) Whelton A : Nephrotoxicity of nonsteroidal anti-inflammatory drugs : physiologic foundations and clinical implications. Am J Med 106 : 13S-24S, 1999.
PubMed
2) 秋元哲, 草野英二 : NSAIDによる薬物性腎障害. 医学のあゆみ 215 : 519-522, 2005.
Medical*Online
3) 薬剤性腎障害の診療ガイドライン作成委員会 (編) : 薬剤性腎障害診療ガイドライン 2016. 日本腎臓学会誌 58 : 477-555, 2016.
 
4) Gambaro G, et al : Adverse renal effects of anti-inflammatory agents : evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253 : 643-652, 2003.
PubMed
5) 大庭梨菜, 坪井伸夫 : 薬剤性腎障害. 非ステロイド性抗炎症薬 (NSAIDs) と腎障害. 腎と透析 91 (増刊) : 667-671, 2021.
 
6) Zhang X, et al : Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease : systematic review and meta-analysis. BMC Nephrol 18 : 256, 2017.
PubMed
7) Nderitu P, et al : Non-steroidal anti-inflammatory drugs and chronic kidney disease progression : a systematic review. Fam Pract 30 : 247-255, 2013.
PubMed
8) Moller B, et al : Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis 74 : 718-723, 2015.
 
9) Palmer BF, Henrich WL : Toxic nephropathy. In : The Kidney, 7th ed (ed by Brenner BM, Rector FC), p1625-1658, W.B. Saunders, Philadelphia, 2004.
 
10) Inoue M, et al : Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure. Clin Exp Nephrol 12 : 296-299, 2008.
PubMed
11) Bakhriansyah M, et al : Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clin J Am Soc Nephrol 14 : 1355-1362, 2019.
PubMed
12) Akimoto T, et al : Low-dose corticosteroid and gallium-67 scintigraphy and acute interstitial nephritis. Saudi J Kidney Dis Transpl 25 : 864-868, 2014.
PubMed
13) Gonzalez E, et al : Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73 : 940-946, 2008.
PubMed
14) 日本腎臓学会 (編) : CKDにおける薬物治療の注意. CKD診療ガイド 2012, p94-99, 東京医学社, 2012.
 
15) 平田純生, ほか : NSAIDs による腎障害COX-2 阻害薬およびアセトアミノフェンは腎障害を起こすか. 日本腎臓学会誌 58 : 1059-1063, 2016.
 
P.320 掲載の参考文献
1) 森博美, 山崎太 : 急性中毒情報ファイル [第4版], 廣川書店, 2008.
 
2) 丹野正敏, ほか : 急性Diquat中毒の一例. 救急医学 7 : 773-775, 1983.
 
3) Hong SY, et al : Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health 19 : 17-23, 2003.
 
4) 高安達典, ほか : 急性農薬中毒 : 1. 有機リン剤. 法医病理 27 : 29-60, 2021.
Medical*Online
5) 友尻重樹, ほか : 急性フェニトロチオン中毒症例における迅速な血清中濃度モニタリングと血漿分離吸着の効果. 中毒研究 11 : 71-75, 1998.
 
6) Nolan CV, Shaikh ZA : Lead nephrotoxicity and associated disorders : biochemical mechanisms. Toxicology 73 : 127-146, 1992.
PubMed
7) Loghman-Adham M : Aminoaciduria and glycosuria following severe childhood lead poisoning. Pediatr Nephrol 12 : 218-221, 1998.
PubMed
8) Schumann GB, et al : Inclusion-bearing cells in industrial workers exposed to lead. Am J Clin Pathol 74 : 192-196, 1980.
PubMed
9) Inglis JA, et al : The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 124 : 65-76, 1978.
PubMed
10) Vesey DA : Transport pathways for cadmium in the intestine and kidney proximal tubule : focus on the interaction with essential metals. Toxicol Lett 198 : 13-19, 2010.
PubMed
11) Yasuda M, et al : Morphometric studies of renal lesions in Itai-itai disease : chronic cadmium nephropathy. Nephron 69 : 14-19, 1995.
PubMed
12) Zalups RK : Molecular interactions with mercury in the kidney. Pharmacol Rev 52 : 113-143, 2000.
PubMed
13) Li SJ, et al : Mercury-induced membranous nephropathy : clinical and pathological features. Clin J Am Soc Nephrol 5 : 439-444, 2010.
PubMed
14) Poldelski V, et al : Ethylene glycol-mediated tubular injury : identification of critical metabolites and injury pathways. Am J Kidney Dis 38 : 339-348, 2001.
PubMed
15) Jacobsen D, McMartin KE : Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol 1 : 309-334, 1986.
PubMed
P.325 掲載の参考文献
1) Naesens M, et al : Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4 : 481-508, 2009.
PubMed
2) Camilleri B, et al : Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation : Where Are We? A Comprehensive Review of the Current Evidence. Exp Clin Transplant 14 : 471-483, 2016.
 
3) Naesens M, et al : The evolution of nonimmune histological injury and its clinical relevance in adult-sized kidney grafts in pediatric recipients. Am J Transplant 7 : 2504-2514, 2007.
PubMed
4) Hertig A, et al : Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 19 : 1584-1591, 2008.
 
5) Kambham N, et al : A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. Clin J Am Soc Nephrol 2 : 135-142, 2007.
PubMed
6) Loupy A, et al : The Banff 2015 Kidney Meeting Report : Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant 17 : 28-41, 2017.
PubMed
7) Verbiest A, et al : De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev 28 : 269-279, 2014.
PubMed
8) Chua JS, et al : Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol 26 : 2239-2247, 2015.
PubMed
9) 薬剤性腎障害の診療ガイドライン作成委員会 (編) : 糸球体腎炎・ネフローゼ症候群に使用する免疫抑制薬. 薬剤性腎障害診療ガイドライン 2016. 日本腎臓学会誌 58 : 525-529, 2016.
 
10) ネフローゼ症候群に対するネオーラルの使用指針-成人ネフローゼ症候群-2011年版 (御手洗哲也, ほか監), ノバルティスファーマ株式会社, 2011年4月.
 
11) Singh L, et al : A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy : an insight for pathogenesis of its toxicity. Hum Pathol 46 : 34-39, 2015.
 
12) Srinivas TR, Meier-Kriesche Hu : Minimizing immunosuppression, an alternative approach to reducing side effects : objectives and interim result. Clin J Am Soc Nephrol 3 (Suppl 2) : S101-S116, 2008.
 
13) Bentata Y : Tacrolimus : 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs 44 : 140-152, 2020.
PubMed
14) Jiang YJ, et al : Nicotine exacerbates tacrolimus-induced renal injury by programmed cell death. Korean J Intern Med 36 : 1437-1449, 2021.
PubMed
15) El Hennawy H, et al : Belatacept rescue therapy of CNI-induced nephrotoxicity, meta-analysis. Transplant Rev (Orlando) 35 : 100653, 2021.
PubMed
P.330 掲載の参考文献
1) 山浦由郎 : 毒キノコと食中毒. 食品と微生物 10 : 113-119, 1993.
 
2) 山浦由郎 : 日本における最近のキノコ中毒発生状況. 中毒研究 26 : 39-43, 2013.
 
3) 農林水産省 : 毒きのこによる食中毒の発生状況. (最終更新日 : 2020年11月6日) [https://www.maff.go.jp/j/syouan/nouan/rinsanbutsu/yaseikinoko/joukyou.html]
 
4) 厚生労働省 : 毒キノコによる食中毒に注意しましょう食中毒発生状況過去のキノコを原因とする食中毒発生状況. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/kinoko/index.html]
 
5) White J, et al : Mushroom poisoning : A proposed new clinical classification. Toxicon 157 : 53-65, 2019.
PubMed
6) Beaumier M, et al : Mushroom Poisoning Presenting With Acute Kidney Injury and Elevated Transaminases. Kidney Int Rep 4 : 877-881, 2019.
PubMed
7) Karlson-Stiber C, Persson H : Cytotoxic fungi--an overview. Toxicon 42 : 339-349, 2003.
PubMed
8) Giannini L, et al : Amatoxin poisoning : A 15-year retrospective analysis and follow-up evaluation of 105 patients. Clin Toxicol (Phila) 45 : 539-542, 2007.
PubMed
9) Busi C, et al : Amanita toxins in gastroduodenal fluid of patients poisoned by the mushroom, Amanita phalloides. N Engl J Med 300 : 800, 1979.
PubMed
10) Koppel C : Clinical symptomatology and management of mushroom poisoning. Toxicon 31 : 1513-1540, 1993.
PubMed
11) Danel VC, et al : Main features of Cortinarius spp. poisoning : a literature review. Toxicon 39 : 1053-1060, 2001.
PubMed
12) Enjalbert F, et al : Treatment of amatoxin poisoning : 20-year retrospective analysis. J Toxicol Clin Toxicol 40 : 715-757, 2002.
PubMed
13) Kirchmair M, et al : Amanita poisonings resulting in acute, reversible renal failure : new cases, new toxic Amanita mushrooms. Nephrol Dial Transplant 27 : 1380-1386, 2012.
PubMed
14) Nilsson UA, et al : The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses. Free Radical Biol Med 44 : 1562-1569, 2008.
PubMed
15) Ronco C : Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 9 : 141-142, 2005.
PubMed
16) 橋本貴美子 : きのこ毒について. モダンメディア64 : 290-297, 2018.
 
P.336 掲載の参考文献
1) 竹本文美, 内田俊也 : 利尿薬による腎障害 ; VIII 中毒性腎障害 (薬物性腎障害, 化学物質による腎障害). 別冊日本臨牀新領域別症候群シリーズ No.17 腎臓症候群 [第2版] 上, p748-753, 日本臨牀社, 2012.
 
2) Patel AM, Goldfarb S : Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 21 : 1440-1443, 2010.
 
3) Novak JE, Ellison DH : Diuretics in States of Volume Overload : Core Curriculum 2022. Am J Kidney Dis 80 : 264-276, 2022.
PubMed
4) Ellison DH : Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol 14 : 1248-1257, 2019.
PubMed
5) van der Aart-van der Beek AB, et al : Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 18 : 294-306, 2022.
PubMed
6) Adrogue HJ, et al : Diagnosis and Management of Hyponatremia : A Review. JAMA 328 : 280-291, 2022.
PubMed
7) Oshima A, et al : Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone. Circ Rep 3 : 333-337, 2021.
PubMed
8) Brater DC : Diuretic therapy. N Engl J Med 339 : 387-395, 1998.
PubMed
9) Greenberg A : Diuretic complications. Am J Med Sci 319 : 10-24, 2000.
PubMed
10) Chonko AM, et al : Treatment of Edema States. In : Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed (ed by Narins RG), p545-582, McGraw-Hill, New York, 1994.
 
P.341 掲載の参考文献
1) Senger DR, et al : Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 : 983-985, 1983.
 
2) Ferrara N, Henzel WJ : Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 : 851-858, 1989.
PubMed
3) Plouet J, et al : Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8 : 3801-3806, 1989.
PubMed
4) Gerber HP, Ferrara N : Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 : 671-680, 2005.
PubMed
5) Gressett SM, Shah SR : Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43 : 490-501, 2009.
PubMed
6) Yang JC, et al : A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 : 427-434, 2003.
PubMed
7) Zhu X, et al : Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor : systematic review and meta-analysis. Am J Kidney Dis 49 : 186-193, 2007.
PubMed
8) Izzedine H : Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol 2014 : 143426, 2014.
PubMed
9) Izzedine H, et al : Kidney diseases associated with anti-vascular endothelial growth factor (VEGF) : an 8-year observational study at a single center. Medicine (Baltimore) 93 : 333-339, 2014.
 
10) Izzedine H, et al : Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85 : 457-470, 2014.
 
11) Feldman DR, et al : Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27 : 1432-1439, 2009.
PubMed
12) Pfister F, et al : Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 73 : 990-1001, 2018.
PubMed
13) Usui J, et al : Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors : a report of 5 cases and review of literature. Hum Pathol 45 : 1918-1927, 2014.
PubMed
14) Dimke H, et al : Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney. J Am Soc Nephrol 26 : 1027-1038, 2015.
 
15) Eremina V, et al : Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 : 707-716, 2003.
PubMed
16) Eremina V, et al : VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 : 1129-1136, 2008.
PubMed
17) Sugimoto H, et al : Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 : 12605-12608, 2003.
PubMed
18) Kitamoto Y, et al : Vascular endothelial growth factor is an essential molecule for mouse kidney development : glomerulogenesis and nephrogenesis. J Clin Invest 99 : 2351-2357, 1997.
PubMed
19) Izzedine H, et al : Proteinuria and VEGF-targeted therapies : an underestimated toxicity? J Nephrol 26 : 807-810, 2013.
PubMed
P.346 掲載の参考文献
1) Herrmann SM, Perazella MA : Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney Int Rep 5 : 1139-1148, 2020.
PubMed
2) Horio Y : [Management of Toxicities of Immune Checkpoint Inhibitors]. Gan To Kagaku Ryoho 44 : 185-190, 2017.
PubMed
3) Cortazar FB, et al : Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90 : 638-647, 2016.
PubMed
4) Cortazar FB, et al : Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI : A Multicenter Study. J Am Soc Nephrol 31 : 435-446, 2020.
 
5) Kitchlu A, et al : A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep 6 : 66-77, 2021.
PubMed
6) Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : ASCO Guideline Update. J Clin Oncol 39 : 4073-4126, 2021.
PubMed
7) Grulich AE, et al : Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients : a meta-analysis. Lancet 370 : 59-67, 2007.
PubMed
8) Murakami N, et al : A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 100 : 196-205, 2021.
 
9) Klajer E, et al : Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis : A systemic review. Semin Oncol 47 : 103-116, 2020.
PubMed
10) Kitchlu A, et al : Immune checkpoint inhibitor use in patients with end-stage kidney disease : an analysis of reported cases and literature review. Clin Kidney J 14 : 2012-2022, 2021.
PubMed
11) Motzer RJ, et al : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1803-1813, 2015.
PubMed
P.351 掲載の参考文献
1) 新臨床腫瘍学 [改訂第5版] (日本臨床腫瘍学会編), 南江堂, 2018.
 
2) Pandey AK, et al : Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension 71 : e1-e8, 2018.
PubMed
3) Estrada CC, et al : Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J Am Soc Nephrol 30 : 187-200, 2019.
PubMed
4) Izzedine H, et al : Kidney diseases associated with anti-vascular endothelial growth factor (VEGF) : an 8-year observational study at a single center. Medicine (Baltimore) 93 : 333-339, 2014.
 
5) Zhang ZF, et al : Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients : a systematic review and meta-analysis. PLoS One 9 : e90135, 2014.
PubMed
6) Cappagli V, et al : Proteinuria is a late-onset adverse event in patients treated with cabozantinib. J Endocrinol Invest 44 : 95-103, 2021.
PubMed
7) Eremina V, et al : VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 : 1129-1136, 2008.
PubMed
8) Izzedine H, et al : VEGF signalling inhibition-induced proteinuria : Mechanisms, significance and management. Eur J Cancer 46 : 439-448, 2010.
PubMed
9) がん薬物療法時の腎障害診療ガイドライン 2016 (日本腎臓学会, 日本癌治療学会, 日本臨床腫瘍学会, 日本腎臓病薬物療法学会編), ライフサイエンス出版, 2016.
 
10) Rini BI, et al : Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103 : 763-773, 2011.
PubMed
11) Bellini E, et al : Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23) -independent mechanism. Ann Oncol 22 : 988-990, 2011.
PubMed
12) Porta C, et al : Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11 : 354-370, 2015.
PubMed
13) Shen H, et al : Assessment of vandetanib as an inhibitor of various human renal transporters : inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab Dispos 41 : 2095-2103, 2013.
PubMed
14) Launay-Vacher V, et al : Renal effects of molecular targeted therapies in oncology : a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26 : 1677-1684, 2015.
PubMed
15) Winn SK, et al : Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib : a class effect? Nephrol Dial Transplant 24 : 673-675, 2009.
PubMed

XIV その他

P.359 掲載の参考文献
1) Albarran J, et al : Retention renale par periureterite. Libration externe de l'uretere. Assoc Fr Urol 9 : 511-517, 1905.
 
2) Ormond JK : Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 59 : 1072-1079, 1948.
PubMed
3) Koep L, Zuidema GD : The clinical significance of retroperitoneal fibrosis. Surgery 81 : 250-257, 1977.
PubMed
4) van Bommel EF, et al : Idiopathic retroperitoneal fibrosis : prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88 : 193-201, 2009.
PubMed
5) 峠弘, ほか : 骨盤腔内に限局し腫瘤形成がみられた特発性後腹膜線維症の1例. 泌尿器科紀要 42 : 577-581, 1996.
 
6) 水島伊知郎, ほか : IgG4 関連動脈周囲炎/後腹膜線維症の臨床像の解析と本疾患に対する特異的診断基準. 脈管学 58 : 117-129, 2018.
 
7) Higgins PM, et al : Non-operative management of retroperitoneal fibrosis. Br J Surg 75 : 573-577, 1988.
PubMed
8) Hamano H, et al : High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344 : 732-738, 2001.
PubMed
9) 松井英男, ほか : スキルス胃癌と鑑別を要する非腫瘍性疾患-後腹膜線維症. 胃と腸 45 : 535-538, 2010.
 
10) Khosroshahi A, et al : International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 67 : 1688-1699, 2015.
PubMed
11) 井上高光, ほか : ステロイド療法が奏効した後腹膜線維症の1例. 泌尿器科紀要 47 : 321-324, 2001.
 
12) 伊與木貴也, ほか : 特発性後腹膜線維症に対する治療成績の検討-IgG4関連疾患の積極的診断を考慮した診断・治療プロトコールの検証-. 泌尿器科紀要 63 : 449-454, 2017.
 
13) Vaglio A, et al : Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis : an open-label randomised controlled trial. Lancet 378 : 338-346, 2011.
PubMed
P.362 掲載の参考文献
1) 濱川隆, ほか : 入院編 : 術後合併症TUR症候群. 臨床泌尿器科 75 : 203-206, 2021.
 
2) Ahyai SA, et al : Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58 : 384-397, 2010.
PubMed
3) Mebust WK, et al : Transurethral prostatectomy : immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol, 141 : 243-247, 1989. J Urol 167 : 5-9, 2002. (DOI : 10.1016/s0022-5347 (05) 65370-0)
 
4) Singh H, et al : Bipolar versus monopolar transurethral resection of prostate : randomized controlled study. J Endourol 19 : 333-338, 2005.
 
5) Michielsen DP, et al : Bipolar transurethral resection in saline-an alternative surgical treatment for bladder outlet obstruction? J Urol 178 : 2035-2039 ; discussion 2039, 2007.
PubMed
6) 櫻井裕之 : TUR-P後の低ナトリウム血症の治療について. LiSA 20 : 209, 2013.
 
7) Moritz ML, et al : 100 cc 3% sodium chloride bolus : a novel treatment for hyponatremic encephalopathy. Metab Brain Dis 25 : 91-96, 2010.
PubMed
8) 足立裕史, ほか : TUR症候群の神経症状-麻酔科学の徒然草か? LiSA 20 : 1037-1039, 2013.
 
9) Weissman JD, et al : Pontine myelinolysis and delayed encephalopathy following the rapid correction of acute hyponatremia. Arch Neurol 46 : 926-927, 1989.
PubMed
P.366 掲載の参考文献
1) Yasui T, et al : Prevalence and epidemiological characteristics of urolithiasis in Japan : national trends between 1965 and 2005. Urology 71 : 209-213, 2008.
PubMed
2) Sakamoto S, et al : Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan. Int J Urol 25 : 373-378, 2018.
PubMed
3) Iguchi M, et al : Inhibitory effects of female sex hormones on urinary stone formation in rats. Kidney Int 56 : 479-485, 1999.
PubMed
4) 井口正典, ほか : 尿路結石症の発生原因に関する検討-夕食から就寝までの間隔が尿路結石症の発生に及ぼす影響について. 日本泌尿器科学会雑誌 80 : 1574-1578, 1989.
 
5) 尿路結石症診療ガイドライン 第2版 (日本泌尿器科学会, 日本泌尿器内視鏡学会, 日本尿路結石症学会編), 金原出版, 2013.
 
6) 濱本周造, ほか : 腹臥位によるECIRS (経皮・経尿道同時内視鏡手術) : 単腎結石に対する治療の工夫. Jpn J Endourol 29 : 55-59, 2016.
 
7) Parsons JK, et al : Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol 177 : 983-987 ; discussion 987, 2007.
 
8) Taguchi K, et al : M1/M2-macrophage phenotypes regulate renal calcium oxalate crystal development. Sci Rep 6 : 35167, 2016.
PubMed
9) Taguchi K, et al : Colony-stimulating factor-1 signaling suppresses renal crystal formation. J Am Soc Nephrol 25 : 1680-1697, 2014.
PubMed
P.372 掲載の参考文献
1) Thiele J, et al : Polycythaemia vera. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition (ed by Swerdlow SH, et al), p39-43, International Agency for Research on Cancer, Lyon, 2017.
 
2) 秋山暢 : X. 検査値赤血球増加. 特集診断ピットフォール-症例から学ぶ. 内科 99 : 1533-1540, 2007.
 
3) Thorling EB : Paraneoplastic erythrocytosis and inappropriate erythropoietin production. A review. Scand J Haematol Suppl 17 : 1-166, 1972.
PubMed
4) 外山圭助 : 腎疾患に伴う赤血球増加症 ; II. 赤血球の異常絶対的赤血球増加症. 別冊日本臨牀領域別症候群シリーズ No.20 血液症候群I, p514-516, 日本臨牀社, 1998.
 
5) Alzoubi B, et al : Post-transplant erythrocytosis after kidney transplantation : A review. World J Transplant 11 : 220-230, 2021.
PubMed
6) Cohen C, et al : Erythrocytosis associated with IgA nephropathy. EBioMedicine 75 : 103785, 2022.
PubMed
7) Erkelens DW, Statius van Eps LW : Bartter's syndrome and erythrocytosis. Am J Med 55 : 711-719, 1973.
PubMed
8) Prchal JT, Thiagarajan P : Chapter 34 : Erythropoiesis and red cell turnover. In : Williams Hematology, 10th Edition (ed by Kaushansky K, et al), McGraw-Hill, New York, 2021.
 
9) Kamihara J, et al : Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med 385 : 2059-2065, 2021.
 
10) Prchal JT : Chapter 58 : Primary and secondary erythropoiesis/polycythemia. In : Williams Hematology, 10th Edition (ed by Kaushansky K, et al), McGraw-Hill, New York, 2021.
 
11) Wiesener MS, et al : Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer 121 : 2434-2442, 2007.
PubMed
12) Friman S, et al : Erythrocytosis after renal transplantation ; treatment by removal of the native kidneys. Nephrol Dial Transplant 5 : 969-973, 1990.
PubMed
13) Mallik N, et al : Congenital erythrocytosis. Eur J Haematol 107 : 29-37, 2021.
PubMed
14) Manal N, et al : Gaisbock syndrome : A review of contemporary studies, pathogenesis, complications, and possible treatment. Cardiol Rev, 2022. (DOI : 10.1097/CRD.0000000000000443)
 
P.375 掲載の参考文献
1) European Society of Urogenital Radiology : ESUR guidelines on contrast agents. 10.0 [https://www.esur.org/esur-guidelines-on-contrast-agents/]
 
2) 対馬義人, ほか : Gadodiamide投与を確認しえたnephrogenic systemic fibrosis (NSF ; 腎性全身性線維症) の1例. 日本透析医学会雑誌 40 : 805-810, 2007.
 
3) Woolen SA, et al : Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent : A Systematic Review and Meta-analysis. JAMA Intern Med 180 : 223-230, 2020.
PubMed
4) Tsushima Y, et al : Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol 36 : 676-685, 2018.
PubMed
5) Amet S, et al : Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents : the Prospective Fibrose Nephrogenique Systemique study. Invest Radiol 49 : 109-115, 2014.
PubMed
6) Alfano G, et al : Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment. Magn Reson Imaging 70 : 1-4, 2020.
PubMed
7) Starekova J, et al : No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid. Radiology 297 : 556-562, 2020.
PubMed
8) Akai H, et al : Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function : A Mouse Model. Radiology 301 : 409-416, 2021.
PubMed
9) Ayers-Ringler J, et al : Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration. Radiology 302 : 676-683, 2022.
PubMed
10) Alkhunizi SM, et al : Gadolinium Retention in the Central and Peripheral Nervous System : Implications for Pain, Cognition, and Neurogenesis. Radiology 297 : 407-416, 2020.
PubMed
11) Erdene K, et al : Organ retention of gadolinium in mother and pup mice : effect of pregnancy and type of gadolinium-based contrast agents. Jpn J Radiol 35 : 568-573, 2017.
PubMed
12) Khairinisa MA, et al : The Effect of Perinatal Gadolinium-Based Contrast Agents on Adult Mice Behavior. Invest Radiol 53 : 110-118, 2018.
PubMed
P.378 掲載の参考文献
1) West CD : Asymptomatic hematuria and proteinuria in children : causes and appropriate diagnostic studies. J Pediatr 89 : 173-182, 1976.
PubMed
2) Arslan Z, Koyun M, Erengin H, et al : Orthostatic proteinuria : an overestimated phenomenon? Pediatr Nephrol 35 : 1935-1940, 2020.
PubMed
3) Rytand DA, Spreiter S : Prognosis in postural (orthostatic) proteinuria : forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 305 : 618-621, 1981.
 
4) 落合友一, ほか : 年齢別にみた運動負荷後の尿蛋白量. 体力科学 40 : 288-297, 1991.
 
5) Vehaskari VM : Mechanism of orthostatic proteinuria. Pediatr Nephrol 4 : 328-330, 1990.
PubMed
6) Mazzoni MB, Kottanatu L, Simonetti GD, et al : Renal vein obstruction and orthostatic proteinuria : a review. Nephrol Dial Transplant 26 : 562-565, 2011.
PubMed
7) Milani G, et al : Body mass index modulates postural proteinuria. Int Urol Nephrol 42 : 513-515, 2010.
PubMed
8) Devarajan P : Mechanisms of orthostatic proteinuria : lessons from a transplant donor. J Am Soc Nephrol 4 : 36-39, 1993.
PubMed
9) Robinson RR, et al : Fixed and reproducible orthostatic proteinuria. I. Light microscopic studies of the kidney. Am J Pathol 39 : 291-306, 1961.
PubMed
10) Springberg PD, et al : Fixed and reproducible orthostatic proteinuria : results of a 20-year follow-up study. Ann Intern Med 97 : 516-519, 1982.
PubMed
P.382 掲載の参考文献
1) 血尿診断ガイドライン 2013 (血尿診断ガイドライン編集委員会編), ライフサイエンス出版, 2013.
 
2) Mugiya S, et al : Ureteroscopic evaluation and laser treatment of chronic unilateral hematuria. J Urol 178 : 517-520, 2007.
PubMed
3) Brito AH, et al : Management of chronic unilateral hematuria by ureterorenoscopy. J Endourol 23 : 1273-1276, 2009.
PubMed
4) Araki M, et al : Ureteroscopic management of chronic unilateral hematuria : a single-center experience over 22 years. PLoS One 7 : e36729, 2012.
PubMed
5) Kumon H, et al : Endoscopic diagnosis and treatment of chronic unilateral hematuria of uncertain etiology. J Urol 143 : 554-558, 1990.
PubMed
6) 中村健治, 山田龍作 : 特発性上部尿路出血の成因に関する臨床的ならびに実験的研究. 日本泌尿器科学会雑誌 72 : 530-543, 1981.
 
7) 公文裕巳 : 原因不明の血尿, 泌尿器科の立場から-特に上部尿路出血について-. 西日本泌尿器科 56 : 511-515, 1994.
 
8) 那須保友, ほか : 腎出血に対する腎盂尿管鏡. Jpn J Endourol ESWL 20 : 199-203, 2007.
 
9) 麦谷荘一, 大園誠一郎 : 腎出血の精査・止血術. Jpn J Endourol ESWL 21 : 78-82, 2008.
Medical*Online
P.386 掲載の参考文献
1) Glazer JL : Management of heatstroke and heat exhaustion. Am Fam Physician 71 : 2133-2140, 2005.
PubMed
2) Epstein Y, Yanovich R : Heatstroke. N Engl J Med 380 : 2449-2459, 2019.
PubMed
3) Rosner MH, Kirven J : Exercise-Associated Hyponatremia. Clin J Am Soc Nephrol 2 : 151-161, 2007.
PubMed
4) Hew-Butler T, et al : Exercise-Associated Hyponatremia : 2017 Update. Front Med (Lausanne) 4 : 21, 2017.
PubMed
5) Argaud L, et al : Short- and long-term outcomes of heatstroke following the 2003 heat wave in Lyon, France. Arch Intern Med 167 : 2177-2183, 2007.
 
6) Thongprayoon C, et al : Impact of Acute Kidney Injury on Outcomes of Hospitalizations for Heat Stroke in the United States. Diseases 8 : 28, 2020.
PubMed
7) Bouchama A, Knochel JP : Heat stroke. N Engl J Med 346 : 1978-1988, 2002.
PubMed
8) Leon LR, Helwig BG : Heat stroke : role of the systemic inflammatory response. J Appl Physiol (1985) 109 : 1980-1988, 2010.
PubMed
9) de Souza AL, et al : Hypoelectrolytemia accompanied by acute renal failure in exertional heatstroke. Am J Emerg Med 24 : 888-889, 2006.
PubMed
10) Pease S, et al : Early organ dysfunction course, cooling time and outcome in classic heatstroke. Intensive Care Med 35 : 1454-1458, 2009.
PubMed
11) Bouchama A, et al : Cooling and hemodynamic management in heatstroke : practical recommendations. Crit Care 11 : R54, 2007.
PubMed
12) Kanda J, et al : Influence of the coronavirus disease 2019 (COVID-19) pandemic on the incidence of heat stroke and heat exhaustion in Japan : a nationwide observational study based on the Heatstroke STUDY 2019 (without COVID-19) and 2020 (with COVID-19). Acute Med Surg 9 : e731, 2022.
PubMed
P.392 掲載の参考文献
1) Vaughan ED, Gillenwater JY : Recovery following complete chronic unilateral ureteral occlusion : functional, radiographic and pathologic alterations. J Urol 106 : 27-35, 1971.
PubMed
2) Okubo K, et al : Recovery of renal function after 153 days of complete unilateral ureteral obstruction. J Urol 160 : 1422-1423, 1998.
PubMed
3) Moody TE, et al : Relationship between renal blood flow and ureteral pressure during 18 hours of total unilateral uretheral occlusion. Implications for changing sites of increased renal resistance. Invest Urol 13 : 246-251, 1975.
PubMed
4) Chevalier RL, et al : Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75 : 1145-1152, 2009.
 
5) Klahr S, et al : Effects of obstruction on renal functions. Pediatr Nephrol 2 : 34-42, 1988.
PubMed
6) Cozzi F, et al : Management of primary megaureter in infancy. J Pediatr Surg 28 : 1031-1033, 1993.
PubMed
7) 低形成・異形成腎を中心とした先天性腎尿路異常 (CAKUT) の腎機能障害進行抑制のためのガイドライン (「腎・泌尿器系の希少・難治性疾患群に関する診断基準・診療ガイドラインの確立」研究班編), 診断と治療社, 2016.
 
8) 日本小児泌尿器科学会 : 小児先天性水腎症 (腎盂尿管移行部通過障害) 診療手引き 2016. Jpn J Pediatr Urol 25 : 1-46, 2016.
 
9) Nguyen HT, et al : The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. J Pediatr Urol 6 : 212-231, 2010.
 
10) Estes JM, Harrison MR : Fetal obstructive uropathy. Semin Pediatr Surg 2 : 129-135, 1993.
PubMed
11) 林祐太郎, ほか : 出生前診断された後部尿道弁の画像所見と出生後の手術治療. 日本小児外科学会雑誌 58 : 385, 2022.
Medical*Online
12) Fedelini P, et al : Intraoperative and postoperative complications of laparoscopic pyeloplasty : a single surgical team experience with 236 cases. J Endourol 27 : 1224-1229, 2013.
 
13) Ito K, et al : Renal damage progresses despite improvement of renal function after relief of unilateral ureteral obstruction in adult rats. Am J Physiol Renal Physiol 287 : F1283-1293, 2004.
PubMed
14) Jones EA, et al : Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. Urology 56 : 346-351, 2000.
PubMed
15) Vaughan ED, et al : Pathophysiology of unilateral ureteral obstruction : studies from Charlottesville to New York. J Urol 172 : 2563-2569, 2004.
PubMed
P.398 掲載の参考文献
1) Laszik ZG, Silva FG : Radiation nephropathy. In : Heptinstall's Pathology of the Kidney, Sixth edition (ed by Jennette JC, et al), p740-753, Lippincott Williams and Wilkins, Philadedelphia, 2006.
 
2) 平田秀紀 : 放射線療法の有害事象. がん・放射線療法2017 (大西洋, ほか編), p101-120, 秀潤社, 2017.
 
3) Cassady JR : Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 31 : 1249-1256, 1995.
PubMed
4) Cohen EP, Robbins MEC : Radiation nephropathy. Semin Nephrol 23 : 486-489, 2003.
PubMed
5) Withers HR, et al : Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 14 : 751-759, 1988.
PubMed
6) Kallman P, et al : Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 62 : 249-262, 1992.
PubMed
7) 平田秀紀 : 放射線治療における医療被曝. 日常診療のための放射線被曝の知識 (臨床放射線 59巻別冊), p100-110, 金原出版, 2014.
 
8) Cheng JC, et al : Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 71 : 1436-1443, 2008.
PubMed
9) Dawson LA, et al : Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 76 : S108-115, 2010.
PubMed
10) Cohen EP, et al : Clinical course of late-onset bone marrow transplant nephropathy. Nephron 64 : 626-635, 1993.
PubMed
11) Miralbell R, et al : Renal toxicity after allogeneic bone marrow transplantation : the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 14 : 579-585, 1996.
PubMed
12) Nevinny-Stickel M, et al : Optimized conformal paraaortic lympth node irradiation is not associated with enhanced renal toxicity. Strahlenther Onkol 183 : 385-391, 2007.
 
13) Cohen EP, et al : Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation : a randomized controlled trial. Int J Radiat Oncol Biol Phys 70 : 1546-1551, 2008.
PubMed
P.401 掲載の参考文献
1) 甲斐祥生 : 一般外来で診る泌尿器系疾患-血尿を中心として [第1版], 南山堂, p123-124, 1984.
 
2) 藤本清秀, 平尾佳彦 : 遊走腎 (腎下垂). 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 (第2版) 下, p868-872, 日本臨牀社, 2012.
 
3) Barber NJ, et al : Nephroptosis and nephropexy--hung up on the past? Eur Urol 46 : 428-433, 2004.
PubMed
4) Ogawa Y, Thompson PM : A case of renal ptosis treated with hochu-ekki-to with improvement confirmed by excretory urography. Hinyokika Kiyo 47 : 649-652, 2001.
 
5) 前川正信 : 腎下垂. 新臨床泌尿器科全書 (市川篤二, 落合京一郎, ほか監), 第9巻 A, p133-139, 金原出版, 1982.
 
6) 南武 : 遊走腎症. 日本泌尿器科全書 第2巻, p449-531, 金原出版, 1961.
 
7) 押木貞雄 : 遊走腎の症状に関する問題点. 日本泌尿器科学会雑誌 62 : 279-297, 1971.
 
8) 中村健治, 山田龍作 : 突発性上部尿路出血の成因に関する臨床的ならびに実験的研究-X線学的立場からみた上部尿路静脈系のうっ滞と血尿との関連について. 日本泌尿器科学会雑誌 72 : 530-543, 1981.
 
9) 秦聡孝, 三股浩光 : 腎下垂 (遊走腎) -長時間の立位で腰背部痛が増強するという患者です. 臨床泌尿器科 69 : 376-377, 2015.
 
10) 大野和美 : 遊走腎における高血圧発生機序に関する研究. 日本泌尿器科学会雑誌 67 : 1070-1084, 1976.
 

XV 補遺

P.409 掲載の参考文献
1) Nakao S, et al : Fabry disease : detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64 : 801-807, 2003.
PubMed
2) 後藤順 : Fabry病. 日本内科学会雑誌 111 : 1541-1547, 2022.
 
3) Inoue T, et al : Newborn screening for Fabry disease in Japan : prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58 : 548-552, 2013.
 
4) Turkmen K, et al : The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey : The TURKFAB Study. Kidney Blood Press Res 41 : 1016-1024, 2016.
PubMed
5) Sugiyama H, et al : Japan Renal Biopsy Registry : the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 15 : 493-503, 2011.
PubMed
6) Kikumoto Y, et al : The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients : a case report and a literature review. Clin Nephrol 78 : 224-229, 2012.
 
7) Saito O, et al : Prevalence of Fabry disease in dialysis patients : Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol 20 : 284-293, 2016.
PubMed
8) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
9) Rolfs A, et al : Acute cerebrovascular disease in the young : the Stroke in Young Fabry Patients study. Stroke 44 : 340-349, 2013.
 
10) Ortiz A, et al : Fabry disease revisited : Management and treatment recommendations for adult patients. Mol Genet Metab 123 : 416-427, 2018.
PubMed
11) Eng CM, et al : Fabry disease : baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30 : 184-192, 2007.
PubMed
12) Yonishi H, et al : Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Nephrol Dial Transplant 37 : 53-62, 2021.
PubMed
13) Fogo AB, et al : Scoring system for renal pathology in Fabry disease : report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25 : 2168-2177, 2010.
 
14) Sakuraba H, et al : Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues ; a pitfall in diagnosis of Fabry disease. J Nephropathol 4 : 91-96, 2015.
PubMed
15) Manabe S, et al : Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies : Not Just in Fabry Disease. Kidney Med 3 : 442-446, 2021.
PubMed
16) Banikazemi M, et al : Agalsidase-beta therapy for advanced Fabry disease : a randomized trial. Ann Intern Med 146 : 77-86, 2007.
PubMed
17) Germain DP, et al : Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18 : 1547-1557, 2007.
PubMed
18) ファブリー病診療ガイドライン 2020 (日本先天代謝異常学会編), 診断と治療社, 2021.
 
19) Hughes DA, et al : Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease : 18-month results from the randomised phase III ATTRACT study. J Med Genet 54 : 288-296, 2017.
PubMed
20) Warnock DG, et al : Antiproteinuric therapy and Fabry nephropathy : factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet 52 : 860-866, 2015.
PubMed
21) Kosch M, et al : Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 66 : 1279-1282, 2004.
PubMed
22) Koga-Kobori S, et al : Fabry Disease on Peritoneal Dialysis with Cardiac Involvement. Intern Med 60 : 1561-1565, 2021.
PubMed
23) Mignani R, et al : Agalsidase therapy in patients with Fabry disease on renal replacement therapy : a nationwide study in Italy. Nephrol Dial Transplant 23 : 1628-1635, 2008.
PubMed
24) Shah T, et al : Kidney transplant outcomes in patients with Fabry disease. Transplantation 87 : 280-285, 2009.
PubMed
25) Inderbitzin D, et al : Kidney transplantation improves survival and is indicated in Fabry's disease. Transplant Proc 37 : 4211-4214, 2005.
PubMed
26) Waldek S, et al : Life expectancy and cause of death in males and females with Fabry disease : findings from the Fabry Registry. Genet Med 11 : 790-796, 2009.
PubMed
27) Thadhani R, et al : Patients with Fabry disease on dialysis in the United States. Kidney Int 61 : 249-255, 2002.
PubMed

書評

最近チェックした商品履歴

Loading...